Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
  • A61K31/713—Double-stranded nucleic acids or oligonucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
  • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
  • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D317/28—Radicals substituted by nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
  • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to the field of therapeutic agent delivery using lipid particles.
• the present invention provides cationic lipids and lipid particles comprising these lipids, which are advantageous for the in vivo delivery of nucleic acids, as well as nucleic acid- lipid particle compositions suitable for in vivo therapeutic use.
• the present invention provides methods of making these compositions, as well as methods of introducing nucleic acids into cells using these compositions, e.g., for the treatment of various disease conditions. Description of the Related Art
• Therapeutic nucleic acids include, e.g., small interfering RNA (siRNA), micro RNA (miRNA), antisense oligonucleotides, ribozymes, plasmids, and immune stimulating nucleic acids. These nucleic acids act via a variety of mechanisms. In the case of siRNA or miRNA, these nucleic acids can down- regulate intracellular levels of specific proteins through a process termed RNA interference (RNAi). Following introduction of siRNA or miRNA into the cell cytoplasm, these double-stranded RNA constructs can bind to a protein termed RISC.
• siRNA small interfering RNA
• miRNA micro RNA
• RNAi RNA interference
• the sense strand of the siRNA or miRNA is displaced from the RISC complex providing a template within RISC that can recognize and bind mRNA with a complementary sequence to that of the bound siRNA or miRNA. Having bound the complementary mRNA the RISC complex cleaves the mRNA and releases the cleaved strands.
• RNAi can provide down-regulation of specific proteins by targeting specific destruction of the corresponding mRNA that encodes for protein synthesis.
• RNAi The therapeutic applications of RNAi are extremely broad, since siRNA and miRNA constructs can be synthesized with any nucleotide sequence directed against a target protein. To date, siRNA constructs have shown the ability to specifically down-regulate target proteins in both in vitro and in vivo models. In addition, siRNA constructs are currently being evaluated in clinical studies.
• siRNA or miRNA constructs Two problems currently faced by siRNA or miRNA constructs are, first, their susceptibility to nuclease digestion in plasma and, second, their limited ability to gain access to the intracellular compartment where they can bind RISC when administered systemically as the free siRNA or miRNA.
• These double-stranded constructs can be stabilized by incorporation of chemically modified nucleotide linkers within the molecule, for example, phosphothioate groups.
• these chemical modifications provide only limited protection from nuclease digestion and may decrease the activity of the construct.
• Intracellular delivery of siRNA or miRNA can be facilitated by use of carrier systems such as polymers, cationic liposomes or by chemical modification of the construct, for example by the covalent attachment of cholesterol molecules [reference].
• Antisense oligonucleotides and ribozymes can also inhibit mRNA translation into protein.
• these single stranded deoxynucleic acids have a complementary sequence to that of the target protein mRNA and can bind to the mRNA by Watson-Crick base pairing. This binding either prevents translation of the target mRNA and/or triggers RNase H degradation of the mRNA transcripts. Consequently, antisense oligonucleotides have tremendous potential for specificity of action (Ae., down-regulation of a specific disease-related protein).
• Antisense can also affect cellular activity by hybridizing specifically with chromosomal DNA. Advanced human clinical assessments of several antisense drugs are currently underway. Targets for these drugs include the bcl2 and apolipoprotein B genes and mRNA products.
• Immune-stimulating nucleic acids include deoxyribonucleic acids and ribonucleic acids. In the case of deoxyribonucleic acids, certain sequences or motifs have been shown to illicit immune stimulation in mammals.
• sequences or motifs include the CpG motif, pyrimidine-rich sequences and palindromic sequences. It is believed that the CpG motif in deoxyribonucleic acids is specifically recognized by an endosomal receptor, toll-like receptor 9 (TLR-9), which then triggers both the innate and acquired immune stimulation pathway. Certain immune stimulating ribonucleic acid sequences have also been reported. It is believed that these RNA sequences trigger immune activation by binding to toll-like receptors 6 and 7 (TLR-6 and TLR-7). In addition, double-stranded RNA is also reported to be immune stimulating and is believe to activate via binding to TLR-3.
• nucleic acid-lipid particles and compositions that are suitable for general therapeutic use.
• these compositions would encapsulate nucleic acids with high-efficiency, have high drug:lipid ratios, protect the encapsulated nucleic acid from degradation and clearance in serum, be suitable for systemic delivery, and provide intracellular delivery of the encapsulated nucleic acid.
• these nucleic acid-lipid particles should be well-tolerated and provide an adequate therapeutic index, such that patient treatment at an effective dose of the nucleic acid is not associated with significant toxicity and/or risk to the patient.
• the present invention provides such compositions, methods of making the compositions, and methods of using the compositions to introduce nucleic acids into cells, including for the treatment of diseases.
• the present invention provides novel amino lipids, as well as lipid particles comprising the same. These lipid particles may further comprise an active agent and be used according to related methods of the invention to deliver the active agent to a cell.
• the present invention includes an amino lipid having the following structure (I): (I) or salts thereof, wherein
• R 1 and R 2 are either the same or different and independently optionally substituted Ci 2 -C 24 alkyl, optionally substituted Ci 2 -C 24 alkenyl, optionally substituted Ci 2 -C 24 alkynyl, or optionally substituted Ci 2 -C 24 acyl;
• R 3 and R 4 are either the same or different and independently optionally substituted CrC 6 alkyl, optionally substituted CrC 6 alkenyl, or optionally substituted CrC 6 alkynyl or R 3 and R 4 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen;
• R 5 is either absent or hydrogen or C r C 6 alkyl to provide a quaternary amine
• m, n, and p are either the same or different and independently either 0 or 1 with the proviso that m, n, and p are not simultaneously 0
• q is 2, 3, or 4;
• Y and Z are either the same or different and independently O, S, or NH.
• the amino lipid is the amino lipid having structure (I) wherein q is 2.
• the amino lipid has the following structure (II):
• R 1 and R 2 are either the same or different and independently optionally substituted Ci 2 -C 24 alkyl, optionally substituted Ci 2 -C 24 alkenyl, optionally substituted Ci 2 -C 24 alkynyl, or optionally substituted Ci 2 -C 24 acyl;
• R 3 and R 4 are either the same or different and independently optionally substituted CrC 6 alkyl, optionally substituted CrC 6 alkenyl, or optionally substituted CrC 6 alkynyl or R 3 and R 4 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen;
• R 5 is either absent or is hydrogen or CrC 6 alkyl to provide a quaternary amine
• m, n, and p are either the same or different and independently either 0 or 1 with the proviso that m, n, and p are not simultaneously 0
• Y and Z are either the same or different and independently O, S, or NH.
• the amino lipid has the following structure (III):
• n 2, 3, or 4.
• the amino lipid has the structure:
• the amino lipid has the structure:
• the amino lipid has the structure:
• the present invention provides an amino lipid having the structure:
• the present invention includes a lipid particle comprising one or more of the above amino lipids of the present invention.
• the particle further comprises a neutral lipid and a lipid capable of reducing particle aggregation.
• the lipid particle consists essentially of: (i) DLin-K-C2-DMA; (ii) a neutral lipid selected from DSPC, POPC, DOPE, and SM; (iii) cholesterol; and (iv) PEG-S-DMG, PEG-C-DOMG or PEG-DMA, in a molar ratio of about 20- 60% DLin-K-C2-DMA:5-25% neutral lipid:25-55% Chol:0.5-15% PEG-S-DMG, PEG-C-DOMG or PEG-DMA.
• the lipid particle consists essentially of: (i) DLin-K 2 -DMA; (ii) a neutral lipid selected from DSPC, POPC, DOPE, and SM; (iii) cholesterol; and (iv) PEG-S-DMG, PEG-C-DOMG or PEG-DMA, in a molar ratio of about 20-60% DLin-K 2 -DMA:5-25% neutral lipid:25-55% Chol:0.5-15% PEG-S-DMG, PEG-C-DOMG or PEG-DMA.
• the present invention includes lipid particles of the invention that further comprise a therapeutic agent.
• the therapeutic agent is a nucleic acid.
• the nucleic acid is a plasmid, an immunostimulatory oligonucleotide, a siRNA, a microRNA, an antisense oligonucleotide, or a ribozyme.
• the present invention includes a pharmaceutical composition comprising a lipid particle o the present invention and a pharmaceutically acceptable excipient, carrier, or diluent.
• the present invention further includes, in other related embodiments, a method of modulating the expression of a polypeptide by a cell, comprising providing to a cell a lipid particle or pharmaceutical composition of the present invention.
• the lipid paticle comprises a therapeutic agent selected from an siRNA, a microRNA, an antisense oligonucleotide, and a plasmid capable of expressing an siRNA, a microRNA, or an antisense oligonucleotide, and wherein the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically binds to a polynucleotide that encodes the polypeptide, or a complement thereof, such that the expression of the polypeptide is reduced.
• the nucleic acid is a plasmid that encodes the polypeptide or a functional variant or fragment thereof, such that expression of the polypeptide or the functional variant or fragment thereof is increased.
• the present invention includes a method of treating a disease or disorder characterized by overexpression of a polypeptide in a subject, comprising providing to the subject a lipid particle or pharmaceutical composition of the present invention, wherein the therapeutic agent is selected from an siRNA, a microRNA, an antisense oligonucleotide, and a plasmid capable of expressing an siRNA, a microRNA, or an antisense oligonucleotide, and wherein the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically binds to a polynucleotide that encodes the polypeptide, or a complement thereof.
• the therapeutic agent is selected from an siRNA, a microRNA, an antisense oligonucleotide, and a plasmid capable of expressing an siRNA, a microRNA, or an antisense oligonucleotide
• the siRNA, microRNA, or antisense RNA comprises a polynucleo
• the present invention includes a method of treating a disease or disorder characterized by underexpression of a polypeptide in a subject, comprising providing to the subject the pharmaceutical composition of the present invention, wherein the therapeutic agent is a plasmid that encodes the polypeptide or a functional variant or fragment thereof.
• the present invention includes a method of inducing an immune response in a subject, comprising providing to the subject the pharmaceutical composition of the present invention, wherein the therapeutic agent is an immunostimulatory oligonucleotide.
• the pharmaceutical composition is provided to the patient in combination with a vaccine or antigen.
• the present invention includes a vaccine comprising the lipid particle of the present invention and an antigen associated with a disease or pathogen.
• the lipid particle comprises an immunostimulatory nucleic acid or oligonucleotide.
• the antigen is a tumor antigen.
• the antigen is a viral antigen, a bacterial antigen, or a parasitic antigen.
• the present invention further includes methods of preparing the lipid particles and pharmaceutical compositions of the present invention, as well as kits usedful in the preparation of these lipid particle and pharmaceutical compositions.
• any of the compositions or methods of the present invention may comprise any of the other cationic lipids of the present invention, as described herein, as the cationic lipid.
• the cationic lipid is DLin-K 2 -DMA or DLin-K6-DMA.
• Figure 1 is a diagram of a proposed mechanism of action for the membrane disruptive effects of cationic lipids and a structural diagram of DLinDMA divided into headgroup, linker and hydrocarbon chain domains.
• cationic lipids and endosomal membrane anionic lipids such as phosphatidylserine adopt a cylindrical molecular shape, which is compatible with packing in a bilayer configuration.
• cationic and anionic lipids when cationic and anionic lipids are mixed together, they combine to form an ion pairs where the cross- sectional area of the combined headgroup is less than that of the sum of individual headgroup areas in isolation.
• the ion pair therefore adopts a molecular "cone" shape, which promotes the formation of inverted, non-bilayer phases such as the hexagonal H M phase illustrated.
• Inverted phases do not support bilayer structure and are associated with membrane fusion and membrane disruption (Hafez, I.M., et al., Gene Ther 8, 1188-1196 (2001 ) and Cullis, P. R., et al., Chem Phys Lipids 40, 127-144 (1986)).
• Figures 2A-B are graphs depicting the in vivo silencing activity of nucleic acid-lipid particles comprising various cationic lipids.
• Figure 1A depicts the silencing activity of DLinDAP (T), DLinDMA (A), DLin-K-DMA ( ⁇ ) and DLin-K-C2-DMA (•) formulations in the mouse FVII model. All nucleic acid- lipid particles were prepared using the preformed vesicle (PFV) method and were composed of ionizable cationic lipid, DSPC, cholesterol and PEG-lipid (40/10/40/10 mol/mol) with a FVII siRNA-to-total lipid ratio of -0.05 (wt/wt).
• PFV preformed vesicle
• Figure 3 is a graph depicting the amount of residual FVII following administration of various dosages of the indicated nucleic acid-lipid particle formulations comprising encapsulated FVII siRNA to mice.
• Figure 4 is a graph depicting the amount of residual FVII following administration of various dosages of the indicated nucleic acid-lipid particle formulations comprising encapsulated FVII siRNA to rats.
• Figure 5 is a graph comparing the amount of residual FVII following administration of two nucleic acid-lipid particle formulations (DUn-K- C2-DMA or DLin-K-DMA) comprising encapsulated FVII siRNA to mice or rats.
• Figure 6 is a graph comparing the amount of residual FVII following administration of various concentrations of three different nucleic acid- lipid particle formulations (DLin-K6-DMA, DI_in-K-C2-DMA, and DLin-K-DMA) comprising encapsulated FVII siRNA to mice.
• Figure 7 is a graph depicting the amount of residual FVII following administration of various dosages of the indicated nucleic acid-lipid particle formulations comprising encapsulated FVII si RNA to animals.
• C2 indicates DLin-K-C2-DMA;
• C3 indicates DI_in-K-C3-DMA;
• C4 indicates DLin-K-C4- DMA.
• Figure 8 is a graph showing the amount of residual FVII following administration of various dosages of the nucleic acid-lipid particle formulations comprising the different indicated cationic lipids: DLinDAP (•), DLJnDMA (A), DLin-K-DMA ( ⁇ ), or DLIN-K-C2-DMA ( ⁇ ).
• Figures 9A-B illustrate the efficacy of KC2-SNALP formulations.
• Figure 9A is a graph showing the improved efficacy of KC2-SNALP versus a DLin-K-C2-DMA PFV formulation in mice.
• Figure 9B depicts the efficacy of KC2-SNALP in non-human primates.
• the present invention is based, in part, upon the identification of novel cationic lipids that provide superior results when used in lipid particles for the in vivo delivery of a therapeutic agent.
• the present invention provides nucleic acid-lipid particle compositions (also referred to as formulations or liposomal formulations) comprising a cationic lipid according to the present invention that provide increased activity of the nucleic acid and significant tolerability of the compositions in vivo, which is expected to correlate with a significant increase in therapeutic index as compared to nucleic acid-lipid particle compositions previously described.
• RNAi therapeutics As described in the accompanying Examples, a rational design approach was employed for the discovery of novel lipids for use in next- generation lipid particle systems to deliver nucleic acids, including, e.g., RNAi therapeutics. Using this approach, important structure-activity considerations for ionizable cationic lipids were described, and multiple lipids based on the DLJnDMA structure were designed and characterized.
• Nucleic acid-lipid particles comprising the cationic lipid termed DI_in-K-C2-DMA were shown to be well-tolerated in both rodent and non-human primates and exhibited in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents, as well as silencing of a therapeutically significant gene (TTR) in non-human primates.
• TTR silencing achieved in this work (ED 50 ⁇ 0.3 mg/kg), represents a significant improvement in activity relative to previous reports of LNP-siRNA mediated silencing in non-human primates.
• the efficacy observed in this study is believed to represent the highest level of potency observed for an RNAi therapeutic in non-human primates to date.
• the present invention specifically provides for improved compositions for the delivery of siRNA molecules. It is shown herein that these compositions are effective in down- regulating the protein levels and/or mRNA levels of target proteins.
• the lipid particles and compositions of the present invention may be used for a variety of purposes, including the delivery of associated or encapsulated therapeutic agents to cells, both in vitro or in vivo. Accordingly, the present invention provides methods of treating diseases or disorders in a subject in need thereof, by contacting the subject with a lipid particle of the present invention associated with a suitable therapeutic agent.
• the lipid particles of the present invention are particularly useful for the delivery of nucleic acids, including, e.g. , siRNA molecules and plasmids. Therefore, the lipid particles and compositions of the present invention may be used to modulate the expression of target genes and proteins both in vitro and in vivo by contacting cells with a lipid particle of the present in vention associated with a nucleic acid that reduces target gene expression (e.g., an siRNA) or a nucleic acid that may be used to increase expression of a desired protein (e.g., a plasmid encoding the desired protein).
• a nucleic acid that reduces target gene expression e.g., an siRNA
• a nucleic acid that may be used to increase expression of a desired protein e.g., a plasmid encoding the desired protein.
• cationic lipids of the present invention as well as lipid particles and compositions comprising the same, and their use to deliver therapeutic agents and modulate gene and protein expression are described in further detail below.
• the present invention provides novel amino lipids that are advantageously used in lipid particles of the present invention for the in vivo delivery of therapeutic agents to cells, including amino lipids having the following structures.
• the amino lipid has the following structure (I):
• R 1 and R 2 are either the same or different and independently optionally substituted Ci 2 -C 24 alkyl, optionally substituted Ci 2 -C 24 alkenyl, optionally substituted Ci 2 -C 24 alkynyl, or optionally substituted Ci 2 -C 24 acyl;
• R 3 and R 4 are either the same or different and independently optionally substituted CrC 6 alkyl, optionally substituted Ci-C 6 alkenyl, or optionally substituted C I -C ⁇ alkynyl or R 3 and R 4 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen;
• R 5 is either absent or is hydrogen or CrC 6 alkyl to provide a quaternary amine
• m, n, and p are either the same or different and independently either 0 or 1 with the proviso that m, n, and p are not simultaneously 0
• q is 2, 3, or 4;
• Y and Z are either the same or different and independently O, S, or NH.
• Alkyl means a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms.
• Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n- butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, fe/t-butyl, isopentyl, and the like.
• saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like.
• Alkenyl means an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both cis and trans isomers. Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2- pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like. "Alkynyl” means any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons.
• alkynyls include acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1 butynyl, and the like.
• “Acyl” means any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below.
• Heterocycle means a 5- to 7-membered monocyclic, or 7- to 10- membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quatemized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring.
• the heterocycle may be attached via any heteroatom or carbon atom.
• Heterocycles include heteroaryls as defined below.
• Heterocycles include morpholinyl, pyrrol id i no nyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
• Halogen means fluoro, chloro, bromo and iodo.
• the amino lipid has the following structure
• R 1 and R 2 are either the same or different and independently optionally substituted C12-C24 alkyl, optionally substituted C12-C24 alkenyl, optionally substituted Ci 2 -C 24 alkynyl, or optionally substituted C 12 -C 24 acyl;
• R 3 and R 4 are either the same or different and independently optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkenyl, or optionally substituted C 1 -C 6 alkynyl or R 3 and R 4 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen;
• R 5 is either absent or is hydrogen or C 1 -C 6 alkyl to provide a quaternary amine; m, n, and p are either the same or different and independently either 0 or 1 with the proviso that m, n, and p are not simultaneously 0;
• Y and Z are either the same or different and independently O, S, or NH.
• the amino lipid has the following structure
• n is 2.
• an amino lipid of the present invention has one of the following structures:
• an amino lipid of the present invention has one of the following structures:
• the methods of the invention may require the use of protecting groups.
• protecting group methodology is well known to those skilled in the art (see, for example, Protective Groups in Organic Synthesis, Green, T.W. et. al., Wiley-lnterscience, New York City, 1999).
• protecting groups within the context of this invention are any group that reduces or eliminates unwanted reactivity of a functional group.
• a protecting group can be added to a functional group to mask its reactivity during certain reactions and then removed to reveal the original functional group.
• an "alcohol protecting group” is used.
• An “alcohol protecting group” is any group which decreases or eliminates unwanted reactivity of an alcohol functional group.
• Protecting groups can be added and removed using techniques well known in the art.
• the compounds of the present invention may be prepared by known organic synthesis techniques, including the methods described in more detail in the Examples.
• the compounds of structure (I) above may be made by the following Reaction Schemes 1 or 2, wherein all substituents are as defined above unless indicated otherwise.
• Ketone 1 and Grignard reagent 2 wherein P is an alcohol protecting group such as trityl, can be purchased or prepared according to methods known to those of ordinary skill in the art.
• Reaction of 1 and 2 yields alcohol 3.
• Deprotection of 3 for example by treatment with mild acid, followed by bromination with an appropriate bromination reagent, for example phosphorous tribromide, yields 4 and 5 respectively.
• Treatment of bromide 5 with 6 yields the heterocyclic compound 7.
• Treatment of 7 with amine 8 then yields a compound of structure (I) wherein m is 1 and R 5 is absent (9). Further treatement of 9 with chloride 10 yields compounds of structure (I) wherein m is 1 and R 5 is present.
• Ketone 1 and bromide 6 can be purchased or prepared according to methods known to those of ordinary skill in the art. Reaction of 1 and 6 yields heterocycle 12. Treatment of 12 with amine 8 yields compounds of structure (I) wherein m is 0 and R 5 is absent (13). Further treatment of 13 with 10 produces compounds of structure (I) wherein w is 0 and R 5 is present. 2. Reaction Scheme 2
• compounds of this invention can be prepared according to Reaction Scheme 3.
• Compounds 12 and 13 can be purchased or prepared according to methods know to those of ordinary skill in the art. Reaction of 12 and 13 yields a compound of structure (I) where R 5 is absent (14). In other embodiments where R 5 is present, 13 can be treated with 10 to obtain compounds of structure 15.
• compounds of this invention can be prepared according to Reaction Scheme 4.
• Compound 16 can be purchased or prepared according to methods know to those of ordinary skill in the art and reacted with 13 to yield a compound of structure (I) where R 5 is absent (17).
• Other embodiments of structure (I) where R 5 is present can be prepared by treatment of 17 with 10 to yield compounds of structure 18.
• Reaction Scheme 5 Compound 19 can be purchased or prepared according to methods known to those of ordinary skill in the art. Reaction of 19 with formaldehyde followed by removal of an optional alcohol protecting group (P), yields alcohol 20. Bromination of 20 followed by treatment with amine 8 yields 22. Compound 22 can then be treated with n-butyl lithium and R 1 I followed by further treatment with n-butyl lithium and R 2 I to yield a compound of structure (I) where R 5 is absent (23). Further treatment of 23 with 10 yields a compound of structure (I) where R 5 is present (24).
• P optional alcohol protecting group
• the amino lipids of the present invention are cationic lipids.
• amino lipid is meant to include those lipids having one or two fatty acid or fatty alkyl chains and an amino head group (including an alkylamino or dialkylamino group) that may be protonated to form a cationic lipid at physiological pH.
• amino lipids would include those having alternative fatty acid groups and other dialkylamino groups, including those in which the alkyl substituents are different (e.g., N-ethyl-N-methylamino-, N-propyl-N-ethylamino- and the like).
• R 11 and R 12 are both long chain alkyl or acyl groups, they can be the same or different.
• amino lipids having less saturated acyl chains are more easily sized, particularly when the complexes must be sized below about 0.3 microns, for purposes of filter sterilization.
• Amino lipids containing unsaturated fatty acids with carbon chain lengths in the range of Ci 4 to C22 are preferred.
• amino or cationic lipids of the present invention have at least one protonatable or deprotonatable group, such that the lipid is positively charged at a pH at or below physiological pH (e.g. pH 7.4), and neutral at a second pH, preferably at or above physiological pH.
• physiological pH e.g. pH 7.4
• second pH preferably at or above physiological pH.
• protonatable lipids according to the invention have a pKa of the protonatable group in the range of about 4 to about 11. Most preferred is pKa of about 4 to about 7, because these lipids will be cationic at a lower pH formulation stage, while particles will be largely (though not completely) surface neutralized at physiological pH around pH 7.4.
• pKa of the protonatable group in the range of about 4 to about 11. Most preferred is pKa of about 4 to about 7, because these lipids will be cationic at a lower pH formulation stage, while particles will be largely (though not completely) surface neutralized at physiological pH around pH 7.4.
• pKa is that at least some nucleic acid associated with the outside surface of the particle will lose its electrostatic interaction at physiological pH and be removed by simple dialysis; thus greatly reducing the particle's susceptibility to clearance.
• the present invention also provides lipid particles comprising one or more of the amino lipids described above.
• Lipid particles include, but are not limited to, liposomes.
• a liposome is a structure having lipid- containing membranes enclosing an aqueous interior. Liposomes may have one or more lipid membranes.
• the invention contemplates both single-layered liposomes, which are referred to as unilamellar, and multi-layered liposomes, which are referred to as multilamellar.
• lipid particles may also be lipoplexes, which are composed of cationic lipid bilayers sandwiched between DNA layers, as described, e.g., in Feigner, Scientific American.
• the lipid particles of the present invention may further comprise one or more additional lipids and/or other components, such as cholesterol.
• Other lipids may be included in the liposome compositions of the present invention for a variety of purposes, such as to prevent lipid oxidation or to attach ligands onto the liposome surface. Any of a number of lipids may be present in liposomes of the present invention, including amphipathic, neutral, cationic, and anionic lipids. Such lipids can be used alone or in combination. Specific examples of additional lipid components that may be present are described below.
• lipid particles of the present invention comprise an amino lipid described above, a non-cationic or neutral lipid, and a conjugated lipid that inhibits particle aggregation.
• lipid particles of the present invention comprise an amino lipid described above, a non-cationic or neutral lipid, a sterol, and a conjugated lipid that inhibits particle aggregation.
• these lipid particles further comprise a cationic lipid in addition to the amino lipid of the present invention.
• Additional components that may be present in a lipid particle of the present invention include bilayer stabilizing components such as polyamide oligomers (see, e.g., U.S. Patent No.
• PEG polyethylene glycol
• PAO polyamide oligomers
• ATTA-lipids are described, e.g., in U.S. Patent No. 6,320,017
• PEG-lipid conjugates are described, e.g., in U.S. Patent Nos.
• the concentration of the lipid component selected to reduce aggregation is about 1 to 15% (by mole percent of lipids).
• Specific examples of PEG-modified lipids (or lipid-polyoxyethylene conjugates) that are useful in the present invention can have a variety of "anchoring" lipid portions to secure the PEG portion to the surface of the lipid vesicle.
• PEG-modified lipids examples include PEG-modified phosphatidylethanolamine and phosphatidic acid, PEG-ceramide conjugates (e.g., PEG-CerC14 or PEG-CerC20) which are described in co-pending USSN 08/486,214, incorporated herein by reference, PEG-modified dialkylamines and PEG-modified 1 ,2-diacyloxypropan-3-amines. Particularly preferred are PEG- modified diacylglycerols and dialkylglycerols.
• a PEG-lipid is selected from:
• a sterically-large moiety such as PEG or ATTA are conjugated to a lipid anchor
• the selection of the lipid anchor depends on what type of association the conjugate is to have with the lipid particle. It is well known that mePEG (mw2000)-diastearoylphosphatidylethanolamine (PEG- DSPE) will remain associated with a liposome until the particle is cleared from the circulation, possibly a matter of days. Other conjugates, such as PEG- CerC20 have similar staying capacity. PEG-CerC14, however, rapidly exchanges out of the formulation upon exposure to serum, with a T 1/2 less than 60 mins. in some assays. As illustrated in US Pat.
• aggregation preventing compounds do not necessarily require lipid conjugation to function properly. Free PEG or free ATTA in solution may be sufficient to prevent aggregation. If the particles are stable after formulation, the PEG or ATTA can be dialyzed away before administration to a subject.
• non-cationic lipid refers to any amphipathic lipid as well as any other neutral lipid or anionic lipid.
• Non-cationic lipids used in the lipid particles, e.g., SNALP, of the present invention can be any of a variety of neutral uncharged, zwitterionic, or anionic lipids capable of producing a stable complex.
• neutral lipid refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH.
• lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerols.
• anionic lipid refers to any lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerols, cardiolipins, diacylphosphatidylserines, diacylphosphatidic acids, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutarylphosphatidylethanolamines, lysylphosphatidylglycerols, palmitoyloleyolphosphatidylglycerol (POPG), and other anionic modifying groups joined to neutral lipids.
• phosphatidylglycerols cardiolipins
• diacylphosphatidylserines diacylphosphatidic acids
• N-dodecanoyl phosphatidylethanolamines N-succinyl phosphatidylethanolamines
• Such lipids include, for example diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, dihydrosphingomyelin, cephalin, and cerebrosides.
• the selection of neutral lipids for use in the particles described herein is generally guided by consideration of, e.g., liposome size and stability of the liposomes in the bloodstream.
• the neutral lipid component is a lipid having two acyl groups, (i.e., diacylphosphatidylcholine and diacylphosphatidylethanolamine).
• Lipids having a variety of acyl chain groups of varying chain length and degree of saturation are available or may be isolated or synthesized by well-known techniques. In one group of embodiments, lipids containing saturated fatty acids with carbon chain lengths in the range of Ci 4 to C22 are preferred. In another group of embodiments, lipids with mono or diunsaturated fatty acids with carbon chain lengths in the range of C- 14 to C 22 are used. Additionally, lipids having mixtures of saturated and unsaturated fatty acid chains can be used.
• the neutral lipids used in the present invention are DOPE, DSPC, POPC, or any related phosphatidylcholine.
• the neutral lipids useful in the present invention may also be composed of sphingomyelin, dihydrosphingomyeline, or phospholipids with other head groups, such as serine and inositol.
• Non-limiting examples of non-cationic lipids include phospholipids such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyl
• acyl groups in these lipids are preferably acyl groups derived from fatty acids having C-
• non-cationic lipids include sterols such as cholesterol and derivatives thereof such as cholestanol, cholestanone, cholestenone, and coprostanol.
• the non-cationic lipid present in the lipid particle, e.g., SNALP comprises or consists of cholesterol, e.g., a phospholipid- free SNALP.
• the non-cationic lipid present in the lipid particle, e.g., SNALP comprises or consists of one or more phospholipids, e.g., a cholesterol-free SNALP.
• the non-cationic lipid present in the SNALP comprises or consists of a mixture of one or more phospholipids and cholesterol.
• non-cationic lipids suitable for use in the present invention include nonphosphorous containing lipids such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stereate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyldimethyl ammonium bromide, ceramide, sphingomyelin, and the like.
• nonphosphorous containing lipids such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stereate,
• the non-cationic lipid typically comprises from about 13 mol % to about 49.5 mol %, about 20 mol % to about 45 mol %, about 25 mol % to about 45 mol %, about 30 mol % to about 45 mol %, about 35 mol % to about 45 mol %, about 20 mol % to about 40 mol %, about 25 mol % to about 40 mol %, or about 30 mol % to about 40 mol % of the total lipid present in the particle.
• the sterol component of the lipid mixture when present, can be any of those sterols conventionally used in the field of liposome, lipid vesicle or lipid particle preparation.
• a preferred sterol is cholesterol.
• cationic lipids which carry a net positive charge at about physiological pH, in addition to those specifically described above, may also be included in lipid particles of the present invention.
• cationic lipids include, but are not limited to, N,N-dioleyl-N,N-dimethylammonium chloride (“DODAC”); N-(2,3-dioleyloxy)propyl-N,N-N-triethylammonium chloride (“DOTMA”); N 1 N- distearyl-N,N-dimethylammonium bromide (“DDAB”); N-(2,3- dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (“DOTAP”); 1 ,2- Dioleyloxy-3-trimethylaminopropane chloride salt (“DOTAP.CI”); 3 ⁇ -(N-(N',N'- dimethylaminoethane)-carbamoyl)cholesterol (“DC-Choi”),
• cationic lipids can be used, such as, e.g., LIPOFECTIN (including DOTMA and DOPE, available from GIBCO/BRL), and LIPOFECTAMINE (comprising DOSPA and DOPE, available from GIBCO/BRL).
• LIPOFECTIN including DOTMA and DOPE, available from GIBCO/BRL
• LIPOFECTAMINE comprising DOSPA and DOPE, available from GIBCO/BRL
• a cationic lipid is an amino lipid.
• amphipathic lipids are included in lipid particles of the present invention. "Amphipathic lipids" refer to any suitable material, wherein the hydrophobic portion of the lipid material orients into a hydrophobic phase, while the hydrophilic portion orients toward the aqueous phase.
• Such compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids.
• Representative phospholipids include sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatdylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine, or dilinoleoylphosphatidylcholine.
• phosphorus-lacking compounds such as sphingolipids, glycosphingolipid families, diacylglycerols, and ⁇ -acyloxyacids, can also be used. Additionally, such amphipathic lipids can be readily mixed with other lipids, such as triglycerides and sterols.
• lipid particles of the present invention are programmable fusion lipids.
• Such lipid particles have little tendency to fuse with cell membranes and deliver their payload until a given signal event occurs. This allows the lipid particle to distribute more evenly after injection into an organism or disease site before it starts fusing with cells.
• the signal event can be, for example, a change in pH, temperature, ionic environment, or time.
• a fusion delaying or "cloaking" component such as an ATTA-lipid conjugate or a PEG-lipid conjugate, can simply exchange out of the lipid particle membrane over time.
• a fusion delaying or "cloaking" component such as an ATTA-lipid conjugate or a PEG-lipid conjugate
• lipid particles of this invention it is desirable to target the lipid particles of this invention using targeting moieties that are specific to a cell type or tissue.
• targeting moieties such as ligands, cell surface receptors, glycoproteins, vitamins (e.g., riboflavin) and monoclonal antibodies, has been previously described (see, e.g., U.S. Patent Nos. 4,957,773 and 4,603,044).
• the targeting moieties can comprise the entire protein or fragments thereof.
• Targeting mechanisms generally require that the targeting agents be positioned on the surface of the lipid particle in such a manner that the target moiety is available for interaction with the target, for example, a cell surface receptor.
• lipid particles i.e., liposomes
• hydrophilic polymer chains such as polyethylene glycol (PEG) chains
• a ligand such as an antibody, for targeting the lipid particle is linked to the polar head group of lipids forming the lipid particle.
• the targeting ligand is attached to the distal ends of the PEG chains forming the hydrophilic polymer coating (Klibanov, et al., Journal of Liposome Research 2: 321-334 (1992); Kirpotin et al., FEBS Letters 388: 115-118 (1996)).
• Standard methods for coupling the target agents can be used.
• phosphatidylethanolamine which can be activated for attachment of target agents
• derivatized lipophilic compounds such as lipid-derivatized bleomycin
• Antibody-targeted liposomes can be constructed using, for instance, liposomes that incorporate protein A (see, Renneisen, et al., J. Bio. Chem., 265:16337-16342 (1990) and Leonetti, et al., Proc. Natl. Acad. Sci. (USA), 87:2448-2451 (1990).
• Other examples of antibody conjugation are disclosed in U.S. Patent No.
• targeting moieties can also include other proteins, specific to cellular components, including antigens associated with neoplasms or tumors. Proteins used as targeting moieties can be attached to the liposomes via covalent bonds (see, Heath, Covalent Attachment of Proteins to Liposomes, 149 Methods in Enzymology 111-119 (Academic Press, Inc. 1987)). Other targeting methods include the biotin-avidin system.
• the lipid particle comprises a mixture of an amino lipid of the present invention, neutral lipids (other than an amino lipid), a sterol (e.g., cholesterol) and a PEG-modified lipid (e.g., a PEG- S-DMG, PEG-C-DOMG or PEG-DMA).
• the lipid mixture consists of or consists essentially of an amino lipid of the present invention, a neutral lipid, cholesterol, and a PEG-modified lipid.
• the lipid particle consists of or consists essentially of the above lipid mixture in molar ratios of about 20-70% amino lipid: 5-45% neutral lipid:20-55% cholesterol:0.5-15% PEG-modified lipid.
• the lipid particle consists of or consists essentially of DLin-K-C2-DMA, DSPC, Choi, and either PEG-S-DMG, PEG-C- DOMG or PEG-DMA, e.g., in a molar ratio of about 20-60% DLin-K-C2-DMA: 5- 25% DSPC:25-55% Chol:0.5-15% PEG-S-DMG, PEG-C-DOMG or PEG-DMA.
• the molar lipid ratio is approximately 40/10/40/10 (mol% DLin-K-C2-DMA/DSPC/Chol/PEG-S-DMG or DLin-K-C2-
• the neutral lipid in these compositions is replaced with POPC, DOPE or SM.
• the lipid particle consists of or consists essentially of DLin-K 2 -DMA, DSPC, Choi, and either PEG-S-DMG, PEG-C- DOMG or PEG-DMA, e.g., in a molar ratio of about 20-60% DLin-K 2 -DMA: 5- 25% DSPC:25-55% Chol:0.5-15% PEG-S-DMG, PEG-C-DOMG or PEG-DMA.
• the molar lipid ratio is approximately 40/10/40/10 (mol% DLin-K 2 -DMA /DSPC/Chol/PEG-S-DMG or DLin-K 2 -DMA /DSPC/Chol/PEG-C-DOMG or DLin-K 2 -DMA /DSPC/Chol/PEG-DMA) or 35/15/40/10 mol% DLin-K 2 -DMA /DSPC/Chol/PEG-S-DMG or DLin-K 2 -DMA /DSPC/Chol/PEG-C-DOMG or DLin-K 2 -DMA /DSPC/Chol/PEG-DMA .
• the neutral lipid in these compositions is replaced with POPC, DOPE or SM.
• the lipid particle consists of or consists essentially of DLin-K6-DMA, DSPC, Choi, and either PEG-S-DMG, PEG-C- DOMG or PEG-DMA, e.g., in a molar ratio of about 20-60% DLin-K6-DMA: 5- 25% DSPC:25-55% Chol:0.5-15% PEG-S-DMG, PEG-C-DOMG or PEG-DMA.
• the molar lipid ratio is approximately 40/10/40/10 (mol% DLin-K6-DMA /DSPC/Chol/PEG-S-DMG or DLin-K6-DMA /DSPC/Chol/PEG-C-DOMG or DLin-K6-DMA /DSPC/Chol/PEG-DMA) or 35/15/40/10 mol% DLin-K6-DMA /DSPC/Chol/PEG-S-DMG or DLin-K6-DMA /DSPC/Chol/PEG-C-DOMG or DLin-K6-DMA /DSPC/Chol/PEG-DMA .
• the neutral lipid in these compositions is replaced with POPC, DOPE or SM.
• the present invention includes compositions comprising a lipid particle of the present invention and an active agent, wherein the active agent is associated with the lipid particle.
• the active agent is a therapeutic agent.
• the active agent is encapsulated within an aqueous interior of the lipid particle.
• the active agent is present within one or more lipid layers of the lipid particle.
• the active agent is bound to the exterior or interior lipid surface of a lipid particle.
• “Fully encapsulated” as used herein indicates that the nucleic acid in the particles is not significantly degraded after exposure to serum or a nuclease assay that would significantly degrade the free nucleic acid.
• a fully encapsulated system preferably less than 25% of particle nucleic acid is degraded in a treatment that would normally degrade 100% of free nucleic acid, more preferably less than 10% and most preferably less than 5% of the particle nucleic acid is degraded.
• full encapsulation may be determined by an Oligreen ® assay.
• Oligreen ® is an ultra-sensitive fluorescent nucleic acid stain for quantitating oligonucleotides and single-stranded DNA or RNA in solution (available from Invitrogen Corporation, Carlsbad, CA). Fully encapsulated also suggests that the particles are serum stable, that is, that they do not rapidly decompose into their component parts upon in vivo administration.
• Active agents include any molecule or compound capable of exerting a desired effect on a cell, tissue, organ, or subject. Such effects may be biological, physiological, or cosmetic, for example. Active agents may be any type of molecule or compound, including e.g., nucleic acids, peptides and polypeptides, including, e.g., antibodies, such as, e.g., polyclonal antibodies, monoclonal antibodies, antibody fragments; humanized antibodies, recombinant antibodies, recombinant human antibodies, and PrimatizedTM antibodies, cytokines, growth factors, apoptotic factors, differentiation-inducing factors, cell surface receptors and their ligands; hormones; and small molecules, including small organic molecules or compounds.
• nucleic acids e.g., nucleic acids, peptides and polypeptides
• antibodies such as, e.g., polyclonal antibodies, monoclonal antibodies, antibody fragments
• the active agent is a therapeutic agent, or a salt or derivative thereof.
• Therapeutic agent derivatives may be therapeutically active themselves or they may be prodrugs, which become active upon further modification.
• a therapeutic agent derivative retains some or all of the therapeutic activity as compared to the unmodified agent, while in another embodiment, a therapeutic agent derivative lacks therapeutic activity.
• therapeutic agents include any therapeutically effective agent or drug, such as anti-inflammatory compounds, anti-depressants, stimulants, analgesics, antibiotics, birth control medication, antipyretics, vasodilators, anti-angiogenics, cytovascular agents, signal transduction inhibitors, cardiovascular drugs, e.g., anti-arrhythmic agents, vasoconstrictors, hormones, and steroids.
• therapeutically effective agent or drug such as anti-inflammatory compounds, anti-depressants, stimulants, analgesics, antibiotics, birth control medication, antipyretics, vasodilators, anti-angiogenics, cytovascular agents, signal transduction inhibitors, cardiovascular drugs, e.g., anti-arrhythmic agents, vasoconstrictors, hormones, and steroids.
• the therapeutic agent is an oncology drug, which may also be referred to as an anti-tumor drug, an anti-cancer drug, a tumor drug, an antineoplastic agent, or the like.
• oncology drugs that may be used according to the invention include, but are not limited to, adriamycin, alkeran, allopurinol, altretamine, amifostine, anastrozole, araC, arsenic trioxide, azathioprine, bexarotene, biCNU, bleomycin, busulfan intravenous, busulfan oral, capecitabine (Xeloda), carboplatin, carmustine, CCNU, celecoxib, chlorambucil, cisplatin, cladribine, cyclosporin A, cytarabine, cytosine arabinoside, daunorubicin, Cytoxan, daunorubicin, dexamethasone, de
• lipid particles of the present invention are associated with a nucleic acid, resulting in a nucleic acid-lipid particle.
• the nucleic acid is partiall or fully encapsulated in the lipid particle.
• the term "nucleic acid” is meant to include any oligonucleotide or polynucleotide. Fragments containing up to 50 nucleotides are generally termed oligonucleotides, and longer fragments are called polynucleotides. In particular embodiments, oligonucletoides of the present invention are 20-50 nucleotides in length.
• polynucleotide and “oligonucleotide” refer to a polymer or oligomer of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages.
• polynucleotide and oligonucleotide also includes polymers or oligomers comprising non-naturally occurring monomers, or portions thereof, which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of properties such as, for example, enhanced cellular uptake and increased stability in the presence of nucleases.
• Oligonucleotides are classified as deoxyribooligonucleotides or ribooligonucleotides.
• a deoxyribooligonucleotide consists of a 5-carbon sugar called deoxyribose joined covalently to phosphate at the 5' and 3' carbons of this sugar to form an alternating, unbranched polymer.
• a ribooligonucleotide consists of a similar repeating structure where the 5-carbon sugar is ribose.
• the nucleic acid that is present in a lipid-nucleic acid particle according to this invention includes any form of nucleic acid that is known.
• the nucleic acids used herein can be single-stranded DNA or RNA, or double- stranded DNA or RNA, or DNA-RNA hybrids.
• double-stranded DNA include structural genes, genes including control and termination regions, and self-replicating systems such as viral or plasmid DNA.
• double-stranded RNA include siRNA and other RNA interference reagents.
• Single-stranded nucleic acids include, e.g., antisense oligonucleotides, ribozymes, microRNA, and triplex-forming oligonucleotides.
• Nucleic acids of the present invention may be of various lengths, generally dependent upon the particular form of nucleic acid.
• plasmids or genes may be from about 1 ,000 to 100,000 nucleotide residues in length.
• oligonucleotides may range from about 10 to 100 nucleotides in length.
• oligonucleotides, both single-stranded, double- stranded, and triple-stranded may range in length from about 10 to about 50 nucleotides, from about 20 o about 50 nucleotides, from about 15 to about 30 nucleotides, from about 20 to about 30 nucleotides in length.
• an oligonucleotide (or a strand thereof) of the present invention specifically hybridizes to or is complementary to a target polynucleotide.
• “Specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide. It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable.
• an oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of utility or expression therefrom, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, or, in the case of in vitro assays, under conditions in which the assays are conducted.
• this oligonucleotide includes 1 , 2, or 3 base substitutions as compared to the region of a gene or mRNA sequence that it is targeting or to which it specifically hybridizes.
• nucleic acid-lipid particles of the present invention are associated with RNA interference (RNAi) molecules.
• RNA interference methods using RNAi molecules may be used to disrupt the expression of a gene or polynucleotide of interest.
• small interfering RNA siRNA
• SiRNAs are RNA duplexes normally 21-30 nucleotides long that can associate with a cytoplasmic multi-protein complex known as RNAi-induced silencing complex (RISC).
• RISC RNAi-induced silencing complex
• siRNA can be designed to knock down protein expression with high specificity. Unlike other antisense technologies, siRNA function through a natural mechanism evolved to control gene expression through non-coding RNA. This is generally considered to be the reason why their activity is more potent in vitro and in vivo than either antisense ODN or ribozymes.
• RNAi reagents including siRNAs targeting clinically relevant targets, are currently under pharmaceutical development, as described, e.g., in de Fougerolles, A. et al., Nature Reviews 6:443-453 (2007).
• RNAi molecules While the first described RNAi molecules were RNA: RNA hybrids comprising both an RNA sense and an RNA antisense strand, it has now been demonstrated that DNA sense:RNA antisense hybrids, RNA sense:DNA antisense hybrids, and DNA:DNA hybrids are capable of mediating RNAi (Lamberton, J.S. and Christian, AT., (2003) Molecular Biotechnology 24:111 - 119). Thus, the invention includes the use of RNAi molecules comprising any of these different types of double-stranded molecules. In addition, it is understood that RNAi molecules may be used and introduced to cells in a variety of forms.
• RNAi molecules encompasses any and all molecules capable of inducing an RNAi response in cells, including, but not limited to, double-stranded polynucleotides comprising two separate strands, i.e. a sense strand and an antisense strand, e.g., small interfering RNA (siRNA); polynucleotides comprising a hairpin loop of complementary sequences, which forms a double-stranded region, e.g., shRNAi molecules, and expression vectors that express one or more polynucleotides capable of forming a double-stranded polynucleotide alone or in combination with another polynucleotide.
• siRNA small interfering RNA
• RNA interference may be used to specifically inhibit expression of target polynucleotides. Double-stranded RNA-mediated suppression of gene and nucleic acid expression may be accomplished according to the invention by introducing dsRNA, siRNA or shRNA into cells or organisms. SiRNA may be double-stranded RNA, or a hybrid molecule comprising both RNA and DNA, e.g., one RNA strand and one DNA strand. It has been demonstrated that the direct introduction of siRNAs to a cell can trigger RNAi in mammalian cells (Elshabir, S. M., et al. Nature 411 :494-498 (2001 )).
• RNA silencing (Brown, D. et al. TechNotes 9(1 ):1-7, available at http://www.dot.ambion.dot.com/techlib/tn/91/912.html (9/1/02)).
• RNAi molecules targeting specific polynucleotides can be readily prepared according to procedures known in the art. Structural characteristics of effective siRNA molecules have been identified. Elshabir, S. M. et al. (2001 ) Nature 411 :494-498 and Elshabir, S. M. et al. (2001 ), EMBO 20:6877-6888. Accordingly, one of skill in the art would understand that a wide variety of different siRNA molecules may be used to target a specific gene or transcript.
• siRNA molecules according to the invention are double-stranded and 16 - 30 or 18 - 25 nucleotides in length, including each integer in between. In one embodiment, an siRNA is 21 nucleotides in length.
• siRNAs have 0-7 nucleotide 3' overhangs or 0-4 nucleotide 5' overhangs. In one embodiment, an siRNA molecule has a two nucleotide 3' overhang. In one embodiment, an siRNA is 21 nucleotides in length with two nucleotide 3' overhangs (i.e. they contain a 19 nucleotide complementary region between the sense and antisense strands). In certain embodiments, the overhangs are UU or dTdT 3' overhangs.
• siRNA molecules are completely complementary to one strand of a target DNA molecule, since even single base pair mismatches have been shown to reduce silencing.
• siRNAs may have a modified backbone composition, such as, for example, 2'-deoxy- or 2'- O-methyl modifications.
• the entire strand of the siRNA is not made with either 2' deoxy or 2'-O-modified bases.
• siRNA target sites are selected by scanning the target mRNA transcript sequence for the occurrence of AA dinucleotide sequences. Each AA dinucleotide sequence in combination with the 3' adjacent approximately 19 nucleotides are potential siRNA target sites.
• siRNA target sites are preferentially not located within the 5' and 3' untranslated regions (UTRs) or regions near the start codon (within approximately 75 bases), since proteins that bind regulatory regions may interfere with the binding of the siRNP endonuclease complex (Elshabir, S. et al. Nature 411 :494-498 (2001 ); Elshabir, S. et al. EMBO J. 20:6877-6888 (2001 )).
• potential target sites may be compared to an appropriate genome database, such as BLASTN 2.0.5, available on the NCBI server at www.ncbi.nlm, and potential target sequences with significant homology to other coding sequences eliminated.
• short hairpin RNAs constitute the nucleic acid component of nucleic acid-lipid particles of the present invention.
• Short Hairpin RNA is a form of hairpin RNA capable of sequence- specifically reducing expression of a target gene.
• Short hairpin RNAs may offer an advantage over siRNAs in suppressing gene expression, as they are generally more stable and less susceptible to degradation in the cellular environment. It has been established that such short hairpin RNA-mediated gene silencing works in a variety of normal and cancer cell lines, and in mammalian cells, including mouse and human cells. Paddison, P. et al., Genes Dev. 16(8):948-58 (2002).
• shRNAs contain a stem loop structure. In certain embodiments, they may contain variable stem lengths, typically from 19 to 29 nucleotides in length, or any number in between. In certain embodiments, hairpins contain 19 to 21 nucleotide stems, while in other embodiments, hairpins contain 27 to 29 nucleotide stems.
• loop size is between 4 to 23 nucleotides in length, although the loop size may be larger than 23 nucleotides without significantly affecting silencing activity.
• ShRNA molecules may contain mismatches, for example G-U mismatches between the two strands of the shRNA stem without decreasing potency.
• shRNAs are designed to include one or several G-U pairings in the hairpin stem to stabilize hairpins during propagation in bacteria, for example.
• complementarity between the portion of the stem that binds to the target mRNA (antisense strand) and the mRNA is typically required, and even a single base pair mismatch is this region may abolish silencing. 5' and 3' overhangs are not required, since they do not appear to be critical for shRNA function, although they may be present (Paddison et al. (2002) Genes & Dev. 16(8):948-58).
• miRNAs are a highly conserved class of small RNA molecules that are transcribed from DNA in the genomes of plants and animals, but are not translated into protein.
• Processed miRNAs are single stranded -17- 25 nucleotide (nt) RNA molecules that become incorporated into the RNA- induced silencing complex (RISC) and have been identified as key regulators of development, cell proliferation, apoptosis and differentiation. They are believed to play a role in regulation of gene expression by binding to the 3'-untranslated region of specific mRNAs.
• RISC mediates down-regulation of gene expression through translational inhibition, transcript cleavage, or both. RISC is also implicated in transcriptional silencing in the nucleus of a wide range of eukaryotes.
• a nucleic acid is an antisense oligonucleotide directed to a target polynucleotide.
• antisense oligonucleotide or simply “antisense” is meant to include oligonucleotides that are complementary to a targeted polynucleotide sequence.
• Antisense oligonucleotides are single strands of DNA or RNA that are complementary to a chosen sequence. In the case of antisense RNA, they prevent translation of complementary RNA strands by binding to it.
• Antisense DNA can be used to target a specific, complementary (coding or non-coding) RNA. If binding takes places this DNA/RNA hybrid can be degraded by the enzyme RNase H.
• antisense oligonucleotides contain from about 10 to about 50 nucleotides, more preferably about 15 to about 30 nucleotides.
• the term also encompasses antisense oligonucleotides that may not be exactly complementary to the desired target gene.
• the invention can be utilized in instances where non-target specific-activities are found with antisense, or where an antisense sequence containing one or more mismatches with the target sequence is the most preferred for a particular use.
• Antisense oligonucleotides have been demonstrated to be effective and targeted inhibitors of protein synthesis, and, consequently, can be used to specifically inhibit protein synthesis by a targeted gene.
• antisense oligonucleotides for inhibiting protein synthesis is well established.
• the synthesis of polygalactauronase and the muscarine type 2 acetylcholine receptor are inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U. S. Patent 5,739,119 and U. S. Patent 5,759,829).
• examples of antisense inhibition have been demonstrated with the nuclear protein cyclin, the multiple drug resistance gene (MDG1 ), ICAM-1 , E-selectin, STK-1 , striatal GABA A receptor and human EGF (Jaskulski et a/., Science.
• antisense oligonucleotides are known in the art and can be readily adapted to produce an antisense oligonucleotide that targets any polynucleotide sequence. Selection of antisense oligonucleotide sequences specific for a given target sequence is based upon analysis of the chosen target sequence and determination of secondary structure, T m , binding energy, and relative stability. Antisense oligonucleotides may be selected based upon their relative inability to form dimers, hairpins, or other secondary structures that would reduce or prohibit specific binding to the target mRNA in a host cell.
• Highly preferred target regions of the mRNA include those regions at or near the AUG translation initiation codon and those sequences that are substantially complementary to 5' regions of the mRNA.
• These secondary structure analyses and target site selection considerations can be performed, for example, using v.4 of the OLIGO primer analysis software (Molecular Biology Insights) and/or the BLASTN 2.0.5 algorithm software (Altschul et ai, Nucleic Acids Res. 1997, 25(17):3389-402).
• nucleic acid- lipid particles are associated with ribozymes.
• Ribozymes are RNA-protein complexes having specific catalytic domains that possess endonuclease activity (Kim and Cech, Proc Natl Acad Sci U S A. 1987 Dec; 84(24):8788-92; Forster and Symons, Cell. 1987 Apr 24;49(2):211-20).
• a large number of ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech et ai, Cell.
• Such binding occurs through the target binding portion of an enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA.
• the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base- pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.
• the enzymatic nucleic acid molecule may be formed in a hammerhead, hairpin, a hepatitis ⁇ virus, group I intron or RNaseP RNA (in association with an RNA guide sequence) or Neurospora VS RNA motif, for example.
• hammerhead motifs are described by Rossi et al. Nucleic Acids Res. 1992 Sep 11 ;20(17):4559-65.
• hairpin motifs are described by Hampel et al. (Eur. Pat. Appl. Publ. No. EP 0360257), Hampel and Tritz, Biochemistry 1989 Jun 13;28(12):4929-33; Hampel et al., Nucleic Acids Res.
• enzymatic nucleic acid molecules used according to the invention have a specific substrate binding site which is complementary to one or more of the target gene DNA or RNA regions, and that they have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule.
• the ribozyme constructs need not be limited to specific motifs mentioned herein. Methods of producing a ribozyme targeted to any polynucleotide sequence are known in the art. Ribozymes may be designed as described in Int. Pat. Appl. Publ. No.
• Ribozyme activity can be optimized by altering the length of the ribozyme binding arms or chemically synthesizing ribozymes with modifications that prevent their degradation by serum ribonucleases (see e.g., Int. Pat. Appl. Publ. No. WO 92/07065; Int. Pat. Appl. Publ. No. WO 93/15187; Int. Pat. Appl. Publ. No. WO 91/03162; Eur. Pat. Appl. Publ.
• Nucleic acids associated with lipid paticles of the present invention may be immunostimulatory, including immunostimulatory oligonucleotides (ISS; single-or double-stranded) capable of inducing an immune response when administered to a subject, which may be a mammal or other patient.
• ISS immunostimulatory oligonucleotides
• ISS include, e.g., certain palindromes leading to hairpin secondary structures (see Yamamoto S., et al. (1992) J. Immunol. 148: 4072- 4076), or CpG motifs, as well as other known ISS features (such as multi-G domains, see WO 96/11266).
• the immune response may be an innate or an adaptive immune response.
• the immune system is divided into a more innate immune system, and acquired adaptive immune system of vertebrates, the latter of which is further divided into humoral cellular components.
• the immune response may be mucosal.
• an immunostimulatory nucleic acid is only immunostimulatory when administered in combination with a lipid particle, and is not immunostimulatory when administered in its "free form.” According to the present invention, such an oligonucleotide is considered to be immunostimulatory.
• Immunostimulatory nucleic acids are considered to be non- sequence specific when it is not required that they specifically bind to and reduce the expression of a target polynucleotide in order to provoke an immune response.
• certain immunostimulatory nucleic acids may comprise a seuqence corresponding to a region of a naturally occurring gene or mRNA, but they may still be considered non-sequence specific immunostimulatory nucleic acids.
• the immunostimulatory nucleic acid or oligonucleotide comprises at least one CpG dinucleotide.
• the oligonucleotide or CpG dinucleotide may be unmethylated or methylated.
• the immunostimulatory nucleic acid comprises at least one CpG dinucleotide having a methylated cytosine.
• the nucleic acid comprises a single CpG dinucleotide, wherein the cytosine in said CpG dinucleotide is methylated.
• the nucleic acid comprises the sequence 5' TAACGTTGAGGGGCAT 3' (SEQ ID NO:2).
• the nucleic acid comprises at least two CpG dinucleotides, wherein at least one cytosine in the CpG dinucleotides is methylated. In a further embodiment, each cytosine in the CpG dinucleotides present in the sequence is methylated. In another embodiment, the nucleic acid comprises a plurality of CpG dinucleotides, wherein at least one of said CpG dinucleotides comprises a methylated cytosine. Exemplary immynostimulatory oligonucleotides are shown in Table 1. In one specific embodiment, the nucleic acid comprises the sequence 5 1 TTCCATGACGTTCCTGACGT 3" (SEQ ID NO:1 ).
• the nucleic acid sequence comprises the sequence 5" TCCATGACGTTCCTGACGT 3 1 (SEQ ID NO:31 ), wherein the two cytosines indicated in bold are methylated.
• the ODN is selected from a group of ODNs consisting of ODN #1 , ODN #2, ODN #3, ODN #4, ODN #5, ODN #6, ODN #7, ODN #8, and ODN #9, as shown below. Table 1.
• ODNs Exemplary lmmunostimulatory Oligonucleotides
• ODN 14 is a 15-mer oligonucleotide and ODN 1 is the same oligonucleotide having a thymidine added onto the 5' end making ODN 1 into a 16-mer. No difference in biological activity between ODN 14 and ODN 1 has been detected and both exhibit similar immunostimulatory activity (Mui et al., J
• ODNs oligonucleotides
• ODNs used in the compositions and methods of the present invention have a phosphodiester ("PO”) backbone or a phosphorothioate (“PS”) backbone, and/or at least one methylated cytosine residue in a CpG motif.
• PO phosphodiester
• PS phosphorothioate
• DNA-based antisense oligodeoxynucleotides (ODN) and ribozymes (RNA) represented an exciting new paradigm for drug design and development, but their application in vivo was prevented by endo- and exo- nuclease activity as well as a lack of successful intracellular delivery.
• ODN oligodeoxynucleotides
• RNA ribozymes
• the degradation issue was effectively overcome following extensive research into chemical modifications that prevented the oligonucleotide (oligo) drugs from being recognized by nuclease enzymes but did not inhibit their mechanism of action.
• This research was so successful that antisense ODN drugs in development today remain intact in vivo for days compared to minutes for unmodified molecules (Kurreck, J. 2003, Eur J Biochem 270:1628-44).
• intracellular delivery and mechanism of action issues have so far limited antisense ODN and ribozymes from becoming clinical products.
• RNA duplexes are inherently more stable to nucleases than single stranded DNA or RNA, and unlike antisense ODN, unmodified siRNA show good activity once they access the cytoplasm. Even so, the chemical modifications developed to stabilize antisense ODN and ribozymes have also been systematically applied to siRNA to determine how much chemical modification can be tolerated and if pharmacokinetic and pharmacodynamic activity can be enhanced.
• RNA interference by siRNA duplexes requires an antisense and sense strand, which have different functions. Both are necessary to enable the siRNA to enter RISC, but once loaded the two strands separate and the sense strand is degraded whereas the antisense strand remains to guide RISC to the target mRNA. Entry into RISC is a process that is structurally less stringent than the recognition and cleavage of the target mRNA. Consequently, many different chemical modifications of the sense strand are possible, but only limited changes are tolerated by the antisense strand.
• nucleoside is a base-sugar combination.
• Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside.
• the phosphate group can be linked to either the 2 ⁇ 3' or 5' hydroxyl moiety of the sugar.
• the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure.
• the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide.
• the normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.
• the nucleic acid that is used in a lipid-nucleic acid particle according to this invention includes any form of nucleic acid that is known.
• the nucleic acid may be a modified nucleic acid of the type used previously to enhance nuclease resistance and serum stability.
• acceptable therapeutic products can also be prepared using the method of the invention to formulate lipid-nucleic acid particles from nucleic acids that have no modification to the phosphodiester linkages of natural nucleic acid polymers, and the use of unmodified phosphodiester nucleic acids (i.e., nucleic acids in which all of the linkages are phosphodiester linkages) is a preferred embodiment of the invention.
• Antisense, siRNA, and other oligonucleotides useful in this invention include, but are not limited to, oligonucleotides containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. Modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.
• Modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotri-esters, methyl and other alkyl phosphonates including 3'- alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, phosphoroselenate, methylphosphonate, or O-alkyl phosphotriester linkages, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'.
• modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
• oligonucleosides include, but are not limited to, U.S. Pat. Nos.
• the phosphorothioate backbone modification (Table 2, #1 ), where a non-bridging oxygen in the phosphodiester bond is replaced by sulfur, is one of the earliest and most common means deployed to stabilize nucleic acid drugs against nuclease degradation.
• PS modifications can be made extensively to both siRNA strands without much impact on activity (Kurreck, J., Eur. J. Biochem. 270:1628-44, 2003).
• PS oligos are known to avidly associate non-specifically with proteins resulting in toxicity, especially upon i.v. administration. Therefore, the PS modification is usually restricted to one or two bases at the 3' and 5' ends.
• the boranophosphate linker (Table 2, #2) is a recent modification that is apparently more stable than PS, enhances siRNA activity and has low toxicity (Hall et a/., Nucleic Acids Res. 32:5991-6000, 2004).
• nucleic acids derivatives include those nucleic acids molecules in which the bridging oxygen atoms (those forming the phosphoester linkages) have been replaced with -S-, -NH-, -CH2- and the like.
• the alterations to the antisense, siRNA, or other nucleic acids used will not completely affect the negative charges associated with the nucleic acids.
• the present invention contemplates the use of antisense, siRNA, and other nucleic acids in which a portion of the linkages are replaced with, for example, the neutral methyl phosphonate or phosphoramidate linkages.
• neutral linkages in certain embodiments, less than 80% of the nucleic acid linkages are so substituted, or less than 50% of the linkages are so substituted.
• oligonucleotides may also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
• nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
• Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C or m5c), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5- halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8- thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl
• nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention, including 5- substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5- propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications 1993, CRC Press, Boca Raton, pages 276-278).
• Modified oligonucleotides may also contain one or more substituted sugar moieties.
• the invention includes oligonucleotides that comprise one of the following at the 2 1 position: OH; F; O-, S-, or N-alkyl, O-alkyl-O-alkyl, O-, S-, or N-alkenyl, or O-, S- or N-alkynyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted Ci to C- IO alkyl or C2 to C10 alkenyl and alkynyl.
• oligonucleotides comprise one of the following at the 2' position: Ci to C-io lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O- alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 2 , NO 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties.
• One modification includes 2'-methoxyethoxy (2'-0-CH 2 CH 2 OCH 3 , also known as 2'- O-(2-methoxyethyl) or 2'-MOE) (Martin et al., HeIv. Chim. Acta 1995, 78, 486- 504), i.e., an alkoxyalkoxy group.
• Other modifications include 2'-dimethylaminooxyethoxy, i.e., a O(CH 2 ) 2 ON(CH 3 ) 2 group, also known as 2'- DMAOE, and 2'-dimethylaminoethoxyethoxy (2'-DMAEOE).
• Additional modifications include 2'-methoxy (2'-0-CH 3 ), 2'- aminopropoxy (2'-OCH 2 CH 2 CH 2 NH 2 ) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugars structures include, but are not limited to, U.S. Pat. Nos.
• both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups, although the base units are maintained for hybridization with an appropriate nucleic acid target compound.
• One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties is referred to as a peptide nucleic acid (PNA).
• PNA peptide nucleic acid
• the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone.
• nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
• Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331 ; and 5,719,262. Further teaching of PNA compounds can be found in Nielsen et al., Science 254, 1497-1500 (1991 ).
• Particular embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH 2 -NH-O-CH 2 -, -CH 2 -N(CH 3 ) -0-CH 2 - (referred to as a methylene (methylimino) or MMI backbone) -CH 2 -O-N(CH 3 ) -CH 2 -, -CH 2 - N(CH 3 )-N(CH 3 ) -CH 2 -- and -0-N(CH 3 ) -CH 2 -CH 2 - (wherein the native phosphodiester backbone is represented as -0-P-O-CH 2 --) of the above referenced U.S.
• oligonucleotides of this invention are chimeric oligonucleotides.
• "Chimeric oligonucleotides” or “chimeras,” in the context of this invention, are oligonucleotides that contain two or more chemically distinct regions, each made up of at least one nucleotide.
• oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, e,g., increased nuclease resistance, increased uptake into cells, increased binding affinity for the RNA target) and a region that is a substrate for RNase H cleavage.
• a chimeric oligonucleotide comprises at least one region modified to increase target binding affinity.
• Affinity of an oligonucleotide for its target is routinely determined by measuring the Tm of an oligonucleotide/target pair, which is the temperature at which the oligonucleotide and target dissociate; dissociation is detected spectrophotometrically. The higher the Tm, the greater the affinity of the oligonucleotide for the target.
• the region of the oligonucleotide which is modified to increase target mRNA binding affinity comprises at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-O-alkyl, 2'-O-alkyl-O-alkyl or 2'-fluoro-modified nucleotide.
• modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher Tm ⁇ i.e., higher target binding affinity) than 2'-deoxyoligonucleotides against a given target. The effect of such increased affinity is to greatly enhance oligonucleotide inhibition of target gene expression.
• a chimeric oligonucletoide comprises a region that acts as a substrate for RNAse H.
• oligonucleotides may include any combination of the various modifications described herein
• Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide.
• Such conjugates and methods of preparing the same are known in the art.
• oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of the routineer. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives.
• the present invention relates to methods and compositions for producing lipid-encapsulated nucleic acid particles in which nucleic acids are encapsulated within a lipid layer.
• nucleic acid- lipid particles incorporating siRNA oligonucleotides, are characterized using a variety of biophysical parameters including: (1 ) drug to lipid ratio; (2) encapsulation efficiency; and (3) particle size.
• High drug to lipid rations, high encapsulation efficiency, good nuclease resistance and serum stability and controllable particle size, generally less than 200 nm in diameter are desirable.
• nucleic acid polymer is of significance, since the modification of nucleic acids in an effort to impart nuclease resistance adds to the cost of therapeutics while in many cases providing only limited resistance. Unless stated otherwise, these criteria are calculated in this specification as follows:
• Nucleic acid to lipid ratio is the amount of nucleic acid in a defined volume of preparation divided by the amount of lipid in the same volume. This may be on a mole per mole basis or on a weight per weight basis, or on a weight per mole basis.
• the nucleic acid:lipid ratio is calculated after dialysis, chromatography and/or enzyme (e.g., nuclease) digestion has been employed to remove as much of the external nucleic acid as possible;
• Encapsulation efficiency refers to the drug to lipid ratio of the starting mixture divided by the drug to lipid ratio of the final, administration competent formulation. This is a measure of relative efficiency.
• Encapsulation efficiency refers to the drug to lipid ratio of the starting mixture divided by the drug to lipid ratio of the final, administration competent formulation. This is a measure of relative efficiency.
• absolute efficiency the total amount of nucleic acid added to the starting mixture that ends up in the administration competent formulation, can also be calculated. The amount of lipid lost during the formulation process may also be calculated. Efficiency is a measure of the wastage and expense of the formulation; and
• Size indicates the size (diameter) of the particles formed. Size distribution may be determined using quasi-elastic light scattering (QELS) on a Nicomp Model 370 sub-micron particle sizer. Particles under 200 nm are preferred for distribution to neo-vascularized (leaky) tissues, such as neoplasms and sites of inflammation.
• QELS quasi-elastic light scattering
• the lipid particles of present invention may be formulated as a pharmaceutical composition, e.g., which further comprises a pharmaceutically acceptable diluent, excipient, or carrier, such as physiological saline or phosphate buffer, selected in accordance with the route of administration and standard pharmaceutical practice.
• a pharmaceutically acceptable diluent, excipient, or carrier such as physiological saline or phosphate buffer, selected in accordance with the route of administration and standard pharmaceutical practice.
• compositions comprising the lipid-nucleic acid particles of the invention are prepared according to standard techniques and further comprise a pharmaceutically acceptable carrier.
• a pharmaceutically acceptable carrier e.g., normal saline will be employed as the pharmaceutically acceptable carrier.
• suitable carriers include, e.g., water, buffered water, 0.9% saline, 0.3% glycine, and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc.
• the carrier is preferably added following lipid particle formation.
• the compositions can be diluted into pharmaceutically acceptable carriers such as normal saline.
• the resulting pharmaceutical preparations may be sterilized by conventional, well known sterilization techniques.
• the aqueous solutions can then be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
• the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
• the lipidic suspension may include lipid- protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage.
• Lipophilic free-radical quenchers such as ⁇ -tocopherol and water-soluble iron-specific chelators, such as ferrioxamine, are suitable.
• concentration of lipid particle or lipid-nucleic acid particle in the pharmaceutical formulations can vary widely, i.e., from less than about 0.01 %, usually at or at least about 0.05-5% to as much as 10 to 30% by weight and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected. For example, the concentration may be increased to lower the fluid load associated with treatment. This may be particularly desirable in patients having atherosclerosis-associated congestive heart failure or severe hypertension.
• complexes composed of irritating lipids may be diluted to low concentrations to lessen inflammation at the site of administration.
• the nucleic acid will have an attached label and will be used for diagnosis (by indicating the presence of complementary nucleic acid).
• the amount of complexes administered will depend upon the particular label used, the disease state being diagnosed and the judgement of the clinician but will generally be between about 0.01 and about 50 mg per kilogram of body weight, preferably between about 0.1 and about 5 mg/kg of body weight.
• the nucleic acid-lipid particles of the invention may include polyethylene glycol (PEG)-modified phospholipids, PEG-ceramide, or ganglioside G M i-modified lipids or other lipids effective to prevent or limit aggregation. Addition of such components does not merely prevent complex aggregation. Rather, it may also provide a means for increasing circulation lifetime and increasing the delivery of the lipid-nucleic acid composition to the target tissues.
• the present invention also provides lipid-therapeutic agent compositions in kit form.
• the kit will typically be comprised of a container that is compartmentalized for holding the various elements of the kit.
• the kit will contain the particles or pharmaceutical compositions of the present invention, preferably in dehydrated or concentrated form, with instructions for their rehydration or dilution and administration.
• the particles comprise the active agent, while in other embodiments, they do not.
• the methods and compositions of the invention make use of certain cationic lipids, the synthesis, preparation and characterization of which is described below and in the accompanying Examples.
• the present invention provides methods of preparing lipid particles, including those associated with a therapeutic agent, e.g., a nucleic acid.
• a therapeutic agent e.g., a nucleic acid.
• any method of preparing nucleic acid-lipid particles may be used according to the present invention by using one or more of the lipids of the present invention in the resulting nucleic acid-lipid particles. Examples of suitable methods are known in the art and described, e.g., in U.S. Patent Application Publication No. 2006/0134189.
• a mixture of lipids is combined with a buffered aqueous solution of nucleic acid to produce an intermediate mixture containing nucleic acid encapsulated in lipid particles wherein the encapsulated nucleic acids are present in a nucleic acid/lipid ratio of about 3 wt% to about 25 wt%, preferably 5 to 15 wt%.
• the intermediate mixture may optionally be sized to obtain lipid-encapsulated nucleic acid particles wherein the lipid portions are unilamellar vesicles, preferably having a diameter of 30 to 150 nm, more preferably about 40 to 90 nm.
• the pH is then raised to neutralize at least a portion of the surface charges on the lipid-nucleic acid particles, thus providing an at least partially surface-neutralized lipid-encapsulated nucleic acid composition.
• lipid vesicles can be formed at the lower pH with titratable cationic lipids and other vesicle components in the presence of nucleic acids. In this manner, the vesicles will encapsulate and entrap the nucleic acids.
• the surface charge of the newly formed vesicles can be neutralized by increasing the pH of the medium to a level above the pK a of the titratable cationic lipids present, i.e., to physiological pH or higher.
• acidic pH e.g. pH 4.0
• the vesicle surface is charged and binds a portion of the nucleic acids through electrostatic interactions.
• a more neutral buffer e.g..
• the surface of the lipid particle or liposome is neutralized, allowing any external nucleic acid to be removed.
• Particularly advantageous aspects of this process include both the facile removal of any surface adsorbed nucleic acid and a resultant nucleic acid delivery vehicle which has a neutral surface. Liposomes or lipid particles having a neutral surface are expected to avoid rapid clearance from circulation and to avoid certain toxicities which are associated with cationic liposome preparations. It is further noted that the vesicles formed in this manner provide formulations of uniform vesicle size with high content of nucleic acids.
• the vesicles have a size range of from about 30 to about 150 nm, more preferably about 30 to about 90 nm. Additional details concerning these uses of such titratable cationic lipids in the formulation of nucleic acid-lipid particles are provided in US Patent 6,287,591 and US Patent 6,858,225, incorporated herein by reference.
• the mixture of lipids includes at least two lipid components: a first amino lipid component of the present invention that is selected from among lipids which have a pKa such that the lipid is cationic at pH below the pKa and neutral at pH above the pKa, and a second lipid component that is selected from among lipids that prevent particle aggregation during lipid-nucleic acid particle formation.
• the amino lipid is a novel cationic lipid of the present invention.
• the mixture of lipids is typically a solution of lipids in an organic solvent.
• This mixture of lipids can then be dried to form a thin film or lyophilized to form a powder before being hydrated with an aqueous buffer to form liposomes.
• the lipid mixture can be solubilized in a water miscible alcohol, such as ethanol, and this ethanolic solution added to an aqueous buffer resulting in spontaneous liposome formation.
• the alcohol is used in the form in which it is commercially available.
• ethanol can be used as absolute ethanol (100%), or as 95% ethanol, the remainder being water. This method is described in more detail in US Patent 5,976,567.
• the mixture of lipids is a mixture of cationic amino lipids, neutral lipids (other than an amino lipid), a sterol (e.g., cholesterol) and a PEG-modified lipid (e.g., a PEG-S-DMG, PEG-C-DOMG or PEG-DMA) in an alcohol solvent.
• the lipid mixture consists essentially of a cationic amino lipid, a neutral lipid, cholesterol and a PEG-modified lipid in alcohol, more preferably ethanol.
• the first solution consists of the above lipid mixture in molar ratios of about 20-70% amino lipid: 5-45% neutral lipid:20-55% cholesterol:0.5- 15% PEG-modified lipid.
• the first solution consists essentially of DLin-K-C2-DMA, DSPC, Choi and PEG-S-DMG, PEG-C-DOMG or PEG-DMA, more preferably in a molar ratio of about 20-60% DLin-K-C2- DMA: 5-25% DSPC:25-55% Chol:0.5-15% PEG-S-DMG, PEG-C-DOMG or PEG-DMA.
• the neutral lipid in these compositions is replaced with POPC, DOPE or SM.
• the lipid mixture is combined with a buffered aqueous solution that may contain the nucleic acids.
• the buffered aqueous solution of is typically a solution in which the buffer has a pH of less than the pK a of the protonatable lipid in the lipid mixture.
• suitable buffers include citrate, phosphate, acetate, and MES.
• a particularly preferred buffer is citrate buffer.
• Preferred buffers will be in the range of 1-1000 mM of the anion, depending on the chemistry of the nucleic acid being encapsulated, and optimization of buffer concentration may be significant to achieving high loading levels (see, e.g., US Patent 6,287,591 and US Patent 6,858,225).
• pure water acidified to pH 5-6 with chloride, sulfate or the like may be useful.
• it may be suitable to add 5% glucose, or another non-ionic solute which will balance the osmotic potential across the particle membrane when the particles are dialyzed to remove ethanol, increase the pH, or mixed with a pharmaceutically acceptable carrier such as normal saline.
• the amount of nucleic acid in buffer can vary, but will typically be from about 0.01 mg/mL to about 200 mg/mL, more preferably from about 0.5 mg/mL to about 50 mg/mL.
• the mixture of lipids and the buffered aqueous solution of therapeutic nucleic acids is combined to provide an intermediate mixture.
• the intermediate mixture is typically a mixture of lipid particles having encapsulated nucleic acids. Additionally, the intermediate mixture may also contain some portion of nucleic acids which are attached to the surface of the lipid particles (liposomes or lipid vesicles) due to the ionic attraction of the negatively-charged nucleic acids and positively-charged lipids on the lipid particle surface (the amino lipids or other lipid making up the protonatable first lipid component are positively charged in a buffer having a pH of less than the pK a of the protonatable group on the lipid).
• the mixture of lipids is an alcohol solution of lipids and the volumes of each of the solutions is adjusted so that upon combination, the resulting alcohol content is from about 20% by volume to about 45% by volume.
• the method of combining the mixtures can include any of a variety of processes, often depending upon the scale of formulation produced. For example, when the total volume is about 10-20 mL or less, the solutions can be combined in a test tube and stirred together using a vortex mixer. Large-scale processes can be carried out in suitable production scale glassware.
• the lipid-encapsulated therapeutic agent e.g., nucleic acid
• the compositions provided herein will be sized to a mean diameter of from about 70 to about 200 nm, more preferably about 90 to about 130 nm.
• Several techniques are available for sizing liposomes to a desired size. One sizing method is described in U.S. Pat. No. 4,737,323, incorporated herein by reference.
• Sonicating a liposome suspension either by bath or probe sonication produces a progressive size reduction down to small unilamellar vesicles (SUVs) less than about 0.05 microns in size.
• Homogenization is another method which relies on shearing energy to fragment large liposomes into smaller ones.
• multilamellar vesicles are recirculated through a standard emulsion homogenizer until selected liposome sizes, typically between about 0.1 and 0.5 microns, are observed.
• the particle size distribution can be monitored by conventional laser-beam particle size determination.
• extrusion is used to obtain a uniform vesicle size.
• Extrusion of liposome compositions through a small-pore polycarbonate membrane or an asymmetric ceramic membrane results in a relatively well-defined size distribution.
• the suspension is cycled through the membrane one or more times until the desired liposome complex size distribution is achieved.
• the liposomes may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in liposome size.
• the lipid-nucleic acid compositions which are formed can be used without any sizing.
• methods of the present invention further comprise a step of neutralizing at least some of the surface charges on the lipid portions of the lipid-nucleic acid compositions.
• unencapsulated nucleic acid is freed from the lipid particle surface and can be removed from the composition using conventional techniques.
• unencapsulated and surface adsorbed nucleic acids are removed from the resulting compositions through exchange of buffer solutions.
• buffer solutions For example, replacement of a citrate buffer (pH about 4.0, used for forming the compositions) with a HEPES-buffered saline (HBS pH about 7.5) solution, results in the neutralization of liposome surface and nucleic acid release from the surface.
• the released nucleic acid can then be removed via chromatography using standard methods, and then switched into a buffer with a pH above the pKa of the lipid used.
• the lipid vesicles can be formed by hydration in an aqueous buffer and sized using any of the methods described above prior to addition of the nucleic acid, according to the preformed vesicle (PFV) method.
• the aqueous buffer should be of a pH below the pKa of the amino lipid.
• a solution of the nucleic acids can then be added to these sized, preformed vesicles.
• the mixture should contain an alcohol, such as ethanol. In the case of ethanol, it should be present at a concentration of about 20% (w/w) to about 45% (w/w).
• nucleic acid encapsulation process it may be necessary to warm the mixture of pre-formed vesicles and nucleic acid in the aqueous buffer- ethanol mixture to a temperature of about 25° C to about 50° C depending on the composition of the lipid vesicles and the nature of the nucleic acid. It will be apparent to one of ordinary skill in the art that optimization of the encapsulation process to achieve a desired level of nucleic acid in the lipid vesicles will require manipulation of variable such as ethanol concentration and temperature. Examples of suitable conditions for nucleic acid encapsulation are provided in the Examples. Once the nucleic acids are encapsulated within the prefromed vesicles, the external pH can be increased to at least partially neutralize the surface charge. Unencapsulated and surface adsorbed nucleic acids can then be removed as described above.
• nucleic acid lipid particles are prepared via a continuous mixing method, e.g., a process that includes providing an aqueous solution comprising a nucleic acid such as an siRNA, in a first reservoir, and providing an organic lipid solution in a second reservoir, and mixing the aqueous solution with the organic lipid solution such that the organic solution mixes with the aqueous solution so as to substantially instantaneously produce a liposome encapsulating the nucleic acid.
• a continuous mixing method e.g., a process that includes providing an aqueous solution comprising a nucleic acid such as an siRNA, in a first reservoir, and providing an organic lipid solution in a second reservoir, and mixing the aqueous solution with the organic lipid solution such that the organic solution mixes with the aqueous solution so as to substantially instantaneously produce a liposome encapsulating the nucleic acid.
• nuclic acid lipid particles are produced via a direct dilution process that includes forming a liposome solution and immediately and directly introducing the liposome solution to a collection vessel containing a controlled amount of dilution buffer.
• the collection vessel includes one or more elements configured to stir the contents of the collection vessel to facilitate dilution.
• a third reservoir containing dilution buffer is fluidly coupled to a second mixing region.
• t liposome solution formedin the first mixing region is immediately and directly mixed with the dilution buffer in thesecond mixing region.
• the lipid particles of the present invention may be used to deliver a therapeutic agent to a cell, in vitro or in vivo.
• the therapeutic agent is a nucleic acid, which is delivered to a cell using a nucleic acid-lipid particles of the present invention. While the following description of various methods of using the lipid particles and related pharmaceutical compositions of the present invention are exemplified by description related to nucleic acid-lipid particles, it is understood that these methods and compositions may be readily adapted for the delivery of any therapeutic agent for the treatment of any disease or disorder that would benefit from such treatment.
• the present invention provides methods for introducing a nucleic acid into a cell.
• Preferred nucleic acids for introduction into cells are siRNA, immune-stimulating oligonucleotides, plasmids, antisense oligonucleotides, and ribozymes. These methods may be carried out by contacting the particles or compositions of the present invention with the cells for a period of time sufficient for intracellular delivery to occur.
• compositions of the present invention can be adsorbed to almost any cell type.
• the nucleic acid-lipid particles can either be endocytosed by a portion of the cells, exchange lipids with cell membranes, or fuse with the cells. Transfer or incorporation of the nucleic acid portion of the complex can take place via any one of these pathways. Without intending to be limited with respect to the scope of the invention, it is believed that in the case of particles taken up into the cell by endocytosis the particles then interact with the endosomal membrane, resulting in destabilization of the endosomal membrane, possibly by the formation of non-bilayer phases, resulting in introduction of the encapsulated nucleic acid into the cell cytoplasm.
• the liposome membrane is integrated into the cell membrane and the contents of the liposome combine with the intracellular fluid.
• Contact between the cells and the lipid-nucleic acid compositions when carried out in vitro, will take place in a biologically compatible medium.
• concentration of compositions can vary widely depending on the particular application, but is generally between about 1 ⁇ mol and about 10 mmol.
• treatment of the cells with the lipid-nucleic acid compositions will generally be carried out at physiological temperatures (about 37 0 C) for periods of time from about 1 to 24 hours, preferably from about 2 to 8 hours.
• the delivery of nucleic acids can be to any cell grown in culture, whether of plant or animal origin, vertebrate or invertebrate, and of any tissue or type.
• the cells will be animal cells, more preferably mammalian cells, and most preferably human cells.
• a lipid-nucleic acid particle suspension is added to 60-80% confluent plated cells having a cell density of from about 10 3 to about 10 5 cells/mL, more preferably about 2 x 10 4 cells/mL.
• the concentration of the suspension added to the cells is preferably of from about 0.01 to 20 ⁇ g/mL, more preferably about 1 ⁇ g/mL.
• Typical applications include using well known procedures to provide intracellular delivery of siRNA to knock down or silence specific cellular targets.
• Alternatively applications include delivery of DNA or mRNA sequences that code for therapeutically useful polypeptides.
• compositions of the present invention include introduction of antisense oligonucleotides in cells (see, Bennett, et al., MoI. Pharm. 41 :1023-1033 (1992)).
• compositions of the present invention can also be used for deliver of nucleic acids to cells in vivo, using methods which are known to those of skill in the art.
• methods which are known to those of skill in the art.
• CMV cytomegalovirus
• CAT chloramphenicol acetyltransferase
• Hyde et al., Nature 362:250-256 (1993), incorporated herein by reference, describes the delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to epithelia of the airway and to alveoli in the lung of mice, using liposomes.
• CTR cystic fibrosis transmembrane conductance regulator
• Brigham, et al., Am. J. Med. Sci. 298:278-281 (1989), incorporated herein by reference describes the in vivo transfection of lungs of mice with a functioning prokaryotic gene encoding the intracellular enzyme, chloramphenicol acetyltransferase (CAT).
• CAT chloramphenicol acetyltransferase
• the pharmaceutical compositions are preferably administered parenterally, i.e., intraarticular ⁇ , intravenously, intraperitoneal ⁇ , subcutaneously, or intramuscularly.
• the pharmaceutical compositions are administered intravenously or intraperitoneally by a bolus injection.
• a bolus injection see Stadler, et al., U.S. Patent No. 5,286,634, which is incorporated herein by reference. Intracellular nucleic acid delivery has also been discussed in Straubringer, et al., METHODS IN ENZYMOLOGY, Academic Press, New York.
• the pharmaceutical preparations may be contacted with the target tissue by direct application of the preparation to the tissue.
• the application may be made by topical, "open” or “closed” procedures.
• topical it is meant the direct application of the pharmaceutical preparation to a tissue exposed to the environment, such as the skin, oropharynx, external auditory canal, and the like.
• Open procedures are those procedures which include incising the skin of a patient and directly visualizing the underlying tissue to which the pharmaceutical preparations are applied.
• a surgical procedure such as a thoracotomy to access the lungs, abdominal laparotomy to access abdominal viscera, or other direct surgical approach to the target tissue.
• "Closed" procedures are invasive procedures in which the internal target tissues are not directly visualized, but accessed via inserting instruments through small wounds in the skin.
• the preparations may be administered to the peritoneum by needle lavage.
• the pharmaceutical preparations may be administered to the meninges or spinal cord by infusion during a lumbar puncture followed by appropriate positioning of the patient as commonly practiced for spinal anesthesia or metrazamide imaging of the spinal cord.
• the preparations may be administered through endoscopic devices.
• the lipid-nucleic acid compositions can also be administered in an aerosol inhaled into the lungs (see, Brigham, et al., Am. J. Sci. 298(4):278-281 (1989)) or by direct injection at the site of disease (Culver, Human Gene Therapy, MaryAnn Liebert, Inc., Publishers, New York. pp.70-71 (1994)).
• the methods of the present invention may be practiced in a variety of hosts.
• Preferred hosts include mammalian species, such as humans, non-human primates, dogs, cats, cattle, horses, sheep, and the like.
• the present invention provides a method of modulating the expression of a target polynucleotide or polypeptide. These methods generally comprise contacting a cell with a lipid particle of the present invention that is associated with a nucleic acid capable of modulating the expression of a target polynucleotide or polypeptide.
• modulating refers to altering the expression of a target polynucleotide or polypeptide. In different embodiments, modulating can mean increasing or enhancing, or it can mean decreasing or reducing.
• Methods of measuring the level of expression of a target polynucleotide or polypeptide include, e.g., methods employing reverse transcription- polymerase chain reaction (RT-PCR) and immunohistochemical techniques.
• RT-PCR reverse transcription- polymerase chain reaction
• the level of expression of a target polynucleotide or polypeptide is increased or reduced by at least 10%, 20%, 30%, 40%, 50%, or greater than 50% as compared to an appropriate control value.
• the nucleic acid may be an expression vector that includes a polynucleotide that encodes the desired polypeptide.
• the nucleic acid may be, e.g., an antisense oligonucleotide, siRNA, or microRNA that comprises a polynucleotide sequence that specifically hybridizes to a polnucleotide that encodes the target polypeptide, thereby disrupting expression of the target polynucleotide or polypeptide.
• the nucleic acid may be a plasmid that expresses such an antisense oligonucletoide, siRNA, or microRNA.
• the present invention provides a method of modulating the expression of a polypeptide by a cell, comprising providing to a cell a lipid particle that consists of or consists essentially of DLJn- K-C2-DMA, DSPC, Choi and PEG-S-DMG, PEG-C-DOMG or PEG-DMA, e.g., in a molar ratio of about 20-60% DI_in-K-C2-DMA: 5-25% DSPC:25-55% Chol:0.5-15% PEG-S-DMG, PEG-C-DOMG or PEG-DMA, wherein the lipid particle is assocated with a nucleic acid capable of modulating the expression of the polypeptide.
• the molar lipid ratio is approximately 40/10/40/10 (mol% DLin-K-C2-DMA/DSPC/Chol/PEG-S-DMG).
• the neutral lipid in these compositions is replaced with POPC, DOPE or SM.
• the cationic lipid is replaced with DLin-K 2 -DMA or DLin-K6-DMA.
• the therapeutic agent is selected from an siRNA, a microRNA, an antisense oligonucleotide, and a plasmid capable of expressing an siRNA, a microRNA, or an antisense oligonucleotide, and wherein the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically binds to a polynucleotide that encodes the polypeptide, or a complement thereof, such that the expression of the polypeptide is reduced.
• the nucleic acid is a plasmid that encodes the polypeptide or a functional variant or fragment thereof, such that expression of the polypeptide or the functional variant or fragment thereof is increased.
• the present invention provides a method of treating a disease or disorder characterized by overexpression of a polypeptide in a subject, comprising providing to the subject a pharmaceutical composition of the present invention, wherein the therapeutic agent is selected from an siRNA, a microRNA, an antisense oligonucleotide, and a plasmid capable of expressing an siRNA, a microRNA, or an antisense oligonucleotide, and wherein the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically binds to a polynucleotide that encodes the polypeptide, or a complement thereof.
• the therapeutic agent is selected from an siRNA, a microRNA, an antisense oligonucleotide, and a plasmid capable of expressing an siRNA, a microRNA, or an antisense oligonucleotide
• the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically
• the pharmaceutical composition comprises a lipid particle that consists of or consists essentially of Dl_in-K-C2-DMA, DSPC, Choi and PEG-S-DMG, PEG-C-DOMG or PEG-DMA, e.g., in a molar ratio of about 20-60% DLin-K-C2-DMA: 5-25% DSPC:25-55% Chol:0.5-15% PEG-S- DMG, PEG-C-DOMG or PEG-DMA, wherein the lipid particle is assocated with the therapeutic nucleic acid.
• the molar lipid ratio is approximately 40/10/40/10 (mol% DLin-K-C2-DMA/DSPC/Chol/PEG-S-DMG).
• the neutral lipid in these compositions is replaced with POPC, DOPE or SM.
• the cationic lipid is replaced with DLin-K 2 -DMA or DI_in-K6-DMA.
• the present invention includes a method of treating a disease or disorder characterized by underexpression of a polypeptide in a subject, comprising providing to the subject a pharmaceutical composition of the present invention, wherein the therapeutic agent is a plasmid that encodes the polypeptide or a functional variant or fragment thereof.
• the pharmaceutical composition comprises a lipid particle that consists of or consists essentially of DLin-K-C2-DMA, DSPC, Choi and PEG-S-DMG, PEG-C-DOMG or PEG-DMA, e.g., in a molar ratio of about 20-60% DLin-K-C2-DMA: 5-25% DSPC:25-55% Chol:0.5-15% PEG-S- DMG or PEG-DMA, wherein the lipid particle is assocated with the therapeutic nucleic acid.
• the molar lipid ratio is approximately 40/10/40/10 (mol% DLin-K-C2-DMA/DSPC/Chol/PEG-S-DMG).
• the neutral lipid in these compositions is replaced with POPC, DOPE or SM.
• the cationic lipid is replaced with DLin-K 2 -DMA or DLin-K6-DMA.
• the present invention further provides a method of inducing an immune response in a subject, comprising providing to the subject the pharmaceutical composition of the present invention, wherein the therapeutic agent is an immunostimulatory oligonucleotide.
• the immune response is a humoral or mucosal immune response.
• the pharmaceutical composition comprises a lipid particle that consists of or consists essentially of DLin-K-C2-DMA, DSPC, Choi and PEG-S- DMG, PEG-C-DOMG or PEG-DMA, e.g., in a molar ratio of about 20-60% DLin- K-C2-DMA: 5-25% DSPC:25-55% Chol:0.5-15% PEG-S-DMG, PEG-C-DOMG or PEG-DMA, wherein the lipid particle is assocated with the therapeutic nucleic acid.
• the molar lipid ratio is approximately 40/10/40/10 (mol% DLin-K-C2-DMA/DSPC/Chol/PEG-S-DMG, PEG-C-DOMG or PEG-DMA).
• the neutral lipid in these compositions is replaced with POPC, DOPE or SM.
• the cationic lipid is replaced with DLin-K 2 -DMA or DLin-K6-DMA.
• the pharmaceutical composition is provided to the subject in combination with a vaccine or antigen.
• the present invention itself provides vaccines comprising a lipid particle of the present invention, which comprises an immunostimulatory oligonucleotide, and is also associated with an antigen to which an immune response is desired.
• the antigen is a tumor antigen or is associated with an infective agent, such as, e.g., a virus, bacteria, or parasiste.
• antigens suitable for use in the present invention include, but are not limited to, polypeptide antigens and DNA antigens.
• specific examples of antigens are Hepatitis A, Hepatitis B, small pox, polio, anthrax, influenza, typhus, tetanus, measles, rotavirus, diphtheria, pertussis, tuberculosis, and rubella antigens.
• the antigen is a Hepatitis B recombinant antigen.
• the antigen is a Hepatitis A recombinant antigen.
• the antigen is a tumor antigen. Examples of such tumor-associated antigens are MUC-1 , EBV antigen and antigens associated with Burkitt's lymphoma.
• the antigen is a tyrosinase-related protein tumor antigen recombinant antigen. Those of skill in the art will know of other antigens suitable for use in the present invention.
• Tumor-associated antigens suitable for use in the subject invention include both mutated and non-mutated molecules that may be indicative of single tumor type, shared among several types of tumors, and/or exclusively expressed or overexpressed in tumor cells in comparison with normal cells.
• tumor-specific patterns of expression of carbohydrates, gangliosides, glycolipids and mucins have also been documented.
• Exemplary tumor-associated antigens for use in the subject cancer vaccines include protein products of oncogenes, tumor suppressor genes and other genes with mutations or rearrangements unique to tumor cells, reactivated embryonic gene products, oncofetal antigens, tissue-specific (but not tumor-specific) differentiation antigens, growth factor receptors, cell surface carbohydrate residues, foreign viral proteins and a number of other self proteins.
• tumor-associated antigens include, e.g., mutated antigens such as the protein products of the Ras p21 protooncogenes, tumor suppressor p53 and BCR-abl oncogenes, as well as CDK4, MUM1 , Caspase 8, and Beta catenin; overexpressed antigens such as galectin 4, galectin 9, carbonic anhydrase, Aldolase A, PRAME, Her2/neu, ErbB-2 and KSA, oncofetal antigens such as alpha fetoprotein (AFP), human chorionic gonadotropin (hCG); self antigens such as carcinoembryonic antigen (CEA) and melanocyte differentiation antigens such as Mart 1/Melan A, gplOO, gp75, Tyrosinase, TRP1 and TRP2; prostate associated antigens such as PSA, PAP, PSMA, PSM-P1 and PSM-P2; reactivated embryonic gene
• Pathogens include, but are not limited to, infectious agents, e.g., viruses, that infect mammals, and more particularly humans.
• infectious virus include, but are not limited to: Retroviridae (e.g., human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-I I I/LAV, or HIV-III; and other isolates, such as HIV-LP; Picornaviridae (e.g., polio viruses, hepatitis A virus; enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses); Calciviridae (e.g., strains that cause gastroenteritis); Togaviridae (e.g., equine encephalitis viruses, rubella viruses); Flaviridae (e.g., dengue viruses, encephalitis viruses, yellow fever viruses); Coronoviridae (e.g., coronaviruses); Rhabdovirada
• Paramyxoviridae e.g., parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus
• Orthomyxoviridae e.g., influenza viruses
• Bungavihdae e.g., Hantaan viruses, bunga viruses, phleboviruses and Nairo viruses
• Arena viridae hemorrhagic fever viruses
• Reoviridae e.g., reoviruses, orbiviurses and rotaviruses
• Birnaviridae Hepadnaviridae (Hepatitis B virus); Parvovirida (parvoviruses); Papovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), her
• gram negative and gram positive bacteria serve as antigens in vertebrate animals.
• Such gram positive bacteria include, but are not limited to Pasteurella species, Staphylococci species, and Streptococcus species.
• Gram negative bacteria include, but are not limited to, Escherichia coli, Pseudomonas species, and Salmonella species.
• infectious bacteria include but are not limited to: Helicobacterpyloris, Borelia burgdorferi, Legionella pneumophilia, Mycobacteria sps (e.g., M. tuberculosis, M. avium, M. intracellular, M. kansaii, M.
• Streptococcus pyogenes Group A Streptococcus
• Streptococcus agalactiae Group B Streptococcus
• Streptococcus viridans group
• Streptococcusfaecalis Streptococcus bovis
• Streptococcus anaerobic sps.
• Streptococcus pneumoniae pathogenic Campylobacter sp., Enterococcus sp., Haemophilus infuenzae, Bacillus antracis, corynebacterium diphtheriae, corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium perfringers, Clostridium tet
• infectious fungi examples include, but are not limited to, infectious fungi that infect mammals, and more particularly humans.
• infectious fingi include, but are not limited to: Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, Candida albicans.
• infectious parasites include Plasmodium such as Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax.
• Other infectious organisms i.e., protists
• Other infectious organisms include Toxoplasma gondii.
• DLin-K-DMA was synthesized as shown in the following schematic and described below.
• Anhydrous dimethyl amine was bubbled into an anhydrous THF solution (100 ml_) containing 1.3 g of a mixture of 2,2-dilinoleyl-4-bromomethyl- [1 ,3]-dioxolane (Vl) and dilinoleyl ketone (V) at O 0 C for 10 min.
• the reaction flask was then sealed and the mixture stirred at room temperature for 6 days. Evaporation of the solvent left 1.5 g of a residual.
• the crude product was purified by column chromatography on silica gel (230-400 mesh, 100 mL) and eluted with 0-5% methanol gradient in dichloromethane. This gave 0.8 g of the desired product D ⁇ n-K-DMA.
• DI_in-K-C2-DMA was synthesized as shown in the schematic diagram and description below.
• DLin-K-C3-DMA was synthesized as described and shown in the schematic diagram below.
• K-C4-DMA DLin-K-C4-DMA was synthesized as described and shown in the schematic diagram below.
• DI_in-K6-DMA DI_in-K6-DMA was synthesized as described and shown in the schematic diagram below.
• DLin-M-K-DMA was synthesized as described and shown in the schematic diagram below.
• the crude product was purified by column chromatography on silica gel (230-400 mesh, 100 ml_) with 0-5% ethyl acetate gradient in hexanes as eluent. This resulted in 1.1 g of pure Il as pale oil.
• the crude product was purified by column chromatography on silica gel (230-400 mesh, 100 mL) with 0-3% ethyl acetate gradient in hexanes as eluent. This resulted in 540 g of a mixture of III as a major product and a by-product. The mixture was used in the following step without further purification.
• DLin-K-MPZ was synthesized as described below and shown in the following diagram.
• DO-K-DMA having the structure shown below was prepared using a method similar to the method described in Example 1 for producing D-Lin-K- DMA, except the initial starting material was oleoyl methane sulfonate, instead of linoleyl methane sulfonate.
• DLin-K-TMA.CI was synthesized as described and shown in the schematic diagram below.
• DLin-K-DMA was prepared as described in Example 1. Synthesis of 2,2-Dilinoleyl-4-trimethylamino-[1 ,31-dioxolane Chloride (DLin-K- TMA.I)
• the above crude DLin-K-TMA.I (2.0 g) was dissolved in 100 mL of CH 2 CI 2 in a separatory funnel. 30 mL of 1 N HCI methanol solution was added, and the resulting solution was shaken well. To the solution was added 50 mL of brine and the mixture was shaken well. The organic phase was separated. The aqueous phase was extracted with 10 mL of CH 2 CI 2 . The organic phase and extract were then combined. This completed the first step of ion exchange. The ion exchange step was repeated four more times. The final organic phase was washed with brine (2 x 75 mL) and dried over anhydrous Na 2 SO 4 .
• DLin-K 2 -DMA was synthesized as described and shown in the schematic diagrams below.
• PEG-lipids such as mPEG2000-1 ,2-Di-O-Alkyl-sn3- Carbomoylglyceride (PEG-C-DOMG) were synthesized as shown in the schematic and described below.
• the x in compound III has a value of 45-49, preferably 47-49, and more preferably 49.
• the reaction mixture was then allowed to stir at ambient temperature overnight. Solvents and volatiles were removed under vacuum and the residue was dissolved in DCM (200 mL) and charged on a column of silica gel packed in ethyl acetate. The column was initially eluted with ethyl acetate and subsequently with gradient of 5-10 % methanol in dichloromethane to afford the desired PEG-Lipid IVa as a white solid (105.3Og, 83%).
• MPEG 2OO o-NH 2 III (1.5Og, 0.687 mmol, purchased from NOF Corporation, Japan) and Mb (0.702g, 1.5eq) were dissolved in dichloromethane (20 ml_) under argon.
• the x in compound III has a value of 45- 49, preferably 47-49, and more preferably 49.
• the reaction was cooled to 0 0 C. Pyridine (1 ml_, excess) was added and the reaction stirred overnight. The reaction was monitored by TLC.
• MPEG 2 ooo-NH 2 III (1.5Og, 0.687 mmol, purchased from NOF Corporation, Japan) and Hc (0.76Og, 1.5eq) were dissolved in dichloromethane (20 ml_) under argon.
• the x in compound III has a value of 45-49, preferably 47-49, and more preferably 49.
• the reaction was cooled to 0 0 C. Pyridine (1 ml_, excess) was added and the reaction was stirred overnight. The reaction was monitored by TLC.
• RNAi silencing of specific hepatocyte proteins can be achieved following intravenous (i.v.) administration of siRNA's encapsulated in, or associated with, select nanoparticles designed for intracellular delivery.
• i.v. intravenous
• select nanoparticles designed for intracellular delivery.
• SNALP stable nucleic acid lipid particle
• DLinDMA cationic lipid 1 ,2-dilinoleyloxy-3-dimethylaminopropane
• lipid nanoparticles LN
• FVII Factor VII
• LN-siRNA systems were prepared using the same process, lipid molar ratios and particle size to minimize effects on activity resulting from formulation characteristics other than the cationic lipid.
• Each formulation was administered as a single bolus injection over a range of doses enabling an estimate of the siRNA dose required to reduce FVII serum protein concentrations by 50% after 24 h (ED 50 ).
• DSPC Distearoylphosphatidylcholine
• Cholesterol was purchased from Sigma Chemical Company (St. Louis, Missouri, USA) or Solvay Pharmaceuticals (Weesp, The Netherlands).
• N-[(methoxy poly( ethylene glycol) 2 ooo)carbamyl]- 1 ,2-dimyristyloxlpropyl-3-amine (PEG-C-DMA) and N-[(methoxy poly(ethylene glycol) 2 ooo)succinimidyl]-1 ,2-dimyristyloxlpropyl-3-amine (PEG-S-DMA) were as described by Hayes et a/., J. Control Release 112:280-290 (2006).
• PEG-C-DOMG R-3-[( ⁇ u- methoxy-poly( ethylene glycol)2000)carbamoyl)]-1 ,2-dimyristyloxlpropyl-3-amine
• siRNAs and 2'-OMe oligoribonucleotides were synthesized by Alnylam as described in John et al. (Nature advance online publication, 26 September 2007 (DOI:10.1038/nature06179)). Oligonucleotides were characterized by electrospray mass spectrometry and anion exchange HPLC.
• siRNAs used in these studies were as follows: si-FVII sense, 5' GGAUCAUCUCAAGUCUUACTT 3' (SEQ ID NO:33); si-FVII antisense, 5'- GUAAGACJJUGAGAUGAUCCTT -3' (SEQ ID NO:34); si-Luc sense, 5'-cuuAcGcuGAGuAcuucGATT-3 1 (SEQ ID NO:35); si-Luc antisense, ⁇ '-UCGAAGuACUcAGCGuAAGTT-S' (SEQ ID NO:36), with lower-case letters denoting 2'-O-Me-modified nucleotides; and underlined letters denoting 2'-F-ITiOd if ied nucleotides. All siRNAs contained phosphorothioate linkages between the two thymidines (T) at the 3' end of each strand.
• T thymidines
• Nucleic acid-lipid particles were made using the preformed vesicle (PFV) method, essentially as described in Maurer et al. (Biophys J., 2001 ). Cationic lipid, DSPC, cholesterol and PEG-lipid were solubilised in ethanol at a molar ratio of 40/10/40/10, respectively. The lipid mixture was added to an aqueous buffer (5OmM citrate, pH 4) with mixing to a final ethanol and lipid concentration of 30% (vol/vol) and 6.1 mg/mL respectively and allowed to equilibrate at room temperature for 2 min before extrusion.
• PV vesicle
• the hydrated lipids were extruded through two stacked 80 nm pore-sized filters (Nuclepore) at 22 0 C using a Lipex Extruder (Hope, MJ. et al. Biochim. Biopys. Acta 812:55-65 (1985)) until a vesicle diameter of 70-90 nm, as determined by Nicomp analysis, was obtained. This generally required 1-3 passes.
• the FVII siRNA (solubilised in a 5OmM citrate, pH 4 aqueous solution containing 30% ethanol) was added to the pre-equilibrated (35 0 C) vesicles, at a rate of ⁇ 5ml_/min with mixing.
• the mixture was incubated for a further 30 min at 35 0 C to allow vesicle reorganization and encapsulation of the FVII siRNA.
• the ethanol was then removed and the external buffer replaced with PBS (155mM NaCI, 3mM Na2HPO4, 1 mM KH2PO4, pH 7.5) by either dialysis or tangential flow diafiltration.
• the size distribution of liposomal siRNA formulations was determined using a NICOMP Model 380 Sub-micron particle sizer (PSS NICOMP, Particle Sizing Systems, Santa Barbara, CA). Mean particle diameters were generally in the range 50-120 nm, depending on the lipid composition used. Liposomal siRNA formulations were generally homogeneous and had standard deviations (from the mean particle size) of 20-50 nm, depending on the lipid composition and formulation conditions used.
• siRNA-containing formulations were eluted through the columns (-2.5 cm bed height, 1.5 cm diameter) equilibrated with HBS (145 mM NaCI, 20 mM HEPES, pH 7.5). An aliquot of the initial and eluted sample were assayed for lipid and siRNA content by HPLC and A260, respectively. The percent encapsulation was calculated based on the change in siRNA to lipid ratios between the pre and post column samples.
• Vivapure centrifugal devices an aliquot (0.4 mL, ⁇ 1.5 mg/mL siRNA) of the siRNA-containing formulation was eluted through the positively charged membrane by centrifugation (2000 xg for 5 min). Aliquots of the pre and post column samples were analyzed as described above to determine the amount of free siRNA in the sample.
• siRNA concentration was determined by measuring the absorbance at 260 nm after solubilization of the lipid.
• the lipid was solubilized according to the procedure outlined by Bligh and Dyer (Bligh, et al., Can. J. Biochem. Physiol. 37:911 -917 (1959). Briefly, samples of liposomal siRNA formulations were mixed with chloroform/methanol at a volume ratio of 1 :2.1 :1 (aqueous sample:methanol:chloroform). If the solution was not completely clear (i.e., a single, clear phase) after mixing, an additional 50-100 ml_ (volume recorded) of methanol was added and the sample was remixed.
• Cholesterol, DSPC, PEG-lipid, and the various cationic lipids were measured against reference standards using a Waters Alliance HPLC system consisting of an Alliance 2695 Separations Module (autosampler, HPLC pump, and column heater), a Waters 2424 Evaporative Light Scattering Detector (ELSD), and Waters Empower HPLC software (version 5.00.00.00, build number 1154; Waters Corporation, Milford, MA, USA).
• ELSD Evaporative Light Scattering Detector
• the gas pressure on the ELSD was set at 25 psi, while the nebulizer heater-cooler set point and drift tube temperature set point were set at 100% and 85°C respectively.
• Measured lipid concentrations (mg/mL) were converted to molar concentrations, and relative lipid ratios were expressed as mol% of the total lipid in the formulation.
• Encapsulation Efficiency Trapping efficiencies were determined after removal of external siRNA by tangential flow diafiltration or anion exchange chromatography. siRNA and lipid concentrations were determined (as described above) in the initial formulation incubation mixtures and after tangential flow diafiltration. The siRNA-to-lipid ratio (wt/wt) was determined at both points in the process, and the encapsulation efficiency was determined by taking the ratio of the final and initial siRNA-to-lipid ratio and multiplying the result by 100 to obtain a percentage.
• FVII activity was evaluated in FVII siRNA-treated animals at 24 hours after intravenous (bolus) injection in C57BL/6 mice or 48 hours after intravenous (bolus) injection in SD rats.
• Six to 8 week old, female C57BI/6 mice were obtained from Charles River Laboratories and acclimated for one week prior to use in studies. Animals were held in a pathogen-free environment and all procedures involving animals were performed in accordance with the guidelines established by the Canadian Council on Animal Care
• LN-siRNA systems containing Factor VII siRNA were diluted to the appropriate concentrations in sterile phosphate buffered saline immediately prior to use, and the formulations were administered intravenously via the lateral tail vein in a total volume of 10 ml/kg.
• animals were anaesthetised with Ketamine/Xylazine and blood was collected by cardiac puncture and processed to serum (Microtainer Serum Separator Tubes; Becton Dickinson, Franklin Lakes, NJ, USA). Serum was tested immediately or stored at -7O 0 C for later analysis for serum Factor VII levels.
• FVII was measured using a commercially available kit (Biophenyl)
• FVII KitTM Aniara Corp., Mason, OH
• FVII reduction was determined against untreated control animals, and the results were expressed as % Residual FVII.
• Five dose levels (0.1 , 0.3, 0.5, 1.0, and 3.0 mg/kg) were typically used.
• a fluorescently labeled siRNA (Cy-3 labeled luciferase siRNA, Alnylam Pharmaceuticals) was used to measure the siRNA content in plasma and liver after iv administration of LN-siRNA systems. The measurements were done by first extracting the Cy3-siRNA from the protein-containing biological matrix and then analyzing the amount of Cy-3 label in the extract by fluorescence. Two extraction methods were used, a chloroform/methanol mixture for the plasma samples and a commercial phenol/chloroform mixture (Trizol® reagent) with the tissue samples.
• Plasma blood was collected in EDTA-containing Vacutainer tubes and centrifuged at 1000 xg for 10 min at 4-8oC to isolate the plasma.
• the plasma was transferred to an eppendorf tube and either assayed immediately or stored in a -3O 0 C freezer.
• An aliquot of the plasma (100 ⁇ l_ maximum) was diluted to 500 ⁇ l_ with PBS (145 mM NaCI, 10 mM phosphate, pH 7.5), methanol (1.05 ml_ and chloroform (0.5 ml_) was added, and the sample vortexed to obtain a clear, single phase solution.
• Serum Factor VII levels were determined using the colorimetric Biophen VII assay kit (Anaira, USA). Briefly, serially diluted pooled control serum (200% - 3.125%) and appropriately diluted plasma samples from treated animals were analyzed using the Biophen VII kit according to manufacturer's instructions in 96-well, flat bottom, non-binding polystyrene assay plates (Corning, Corning, NY) and absorbance at 405nm was measured. A calibration curve was generated using the serial diluted control serum and used to determine levels of Factor VII in serum from treated animals.
• the tolerability of empty DLin-K-C2-DMA lipid particles was evaluated by monitoring weight change, cageside observations, clinical chemistry and, in some instances, hematology in femal Sprague Dawley rats and female C57BL/6 mice. Animal weights were recorded prior to treatment and at 24 hours after intravenous treatment with various dosages. Data was recorded as % Change in Body Weight. In addition to body weight measurements, clinical chemistry panel, including liver function markers, was obtained at each dose level at 24 hours post-injection using an aliquot of the serum collected for FVII analysis. Samples were sent to the Central Laboratory for Veterinarians (Langley, BC) for analysis. In some instances, additional animals were included in the treatment group to allow collection of whole blood for hematology analysis.
• the ED 50 for formulations with poor activity is expressed as a range, e.g. 12-25 mg/kg, indicating that a 50% reduction in serum FVII protein levels occurs between these siRNA doses. If a formulation showed good activity (ED 50 ⁇ 2 mg/kg), then the dose response was repeated over a narrower dose range and head-to-head with DLinDMA for greater comparative accuracy. Screen 1a: Headgroup modifications to DLinDMA and in vivo FVII activity
• DLinDMA was divided into three key structural domains that were modified separately, including the headgroup, the linker, and the hydrocarbon chains.
• the dimethylaminopropane headgroup is hydrophilic and contains a tertiary amine function with an apparent pKa (in situ) of pH 6.4. Consequently, DLinDMA is almost completely charged at pH 4, the pH at which the LN-siRNA systems are formed through electrostatic interaction with siRNA. Whereas, at pH 7.4, -5-10% of DLinDMA molecules are charged; therefore, the cationic charge density at the surface of these nanoparticles in the circulation is relatively low.
• the headgroup modifications made to DLinDMA are shown in Table 3, and the first three were designed to alter the nature of the positive charge.
• DLinTMA contains a quaternary amino group and is permanently charged, and showed reduced activity with an estimated ED 50 between 2 - 5 mg/kg.
• a similar decrease in activity was observed when the dimethylamine function was replaced by a piperazine moiety (DLinMPZ, ED 50 2 - 5 mg/kg), and reduced more significantly when substituted by a morpholino group (DLinMA, ED 50 12-25 mg/kg).
• DLinMPZ piperazine moiety
• DLinMA morpholino group
• Lipid degradation was not measured in vivo for any of the lipids screened here, but it is expected that an ethoxy group (DLin-EG-DMA) would be more resistant to enzymatic cleavage than an ester group (DLinDAC) (Martin, B. et al., Curr. Pharm. Des 11 :375-394 (2005)); none the less, both lipids exhibited similar activity.
• Table 3. Headgroup modifications to DLJnDMA
• DLJnDMA has two unsaturated hydrocarbon chains joined to the dimethylaminopropane headgroup through two ethoxy linkages.
• the linker region resides at the membrane interface, an area of transition between the hydrophobic membrane core and hydrophilic headgroup surface.
• the approach to linker modification of DLJnDMA was to introduce linker groups expected to exhibit different rates of chemical or enzymatic stability and spanning a range of hydrophilicity.
• the ethoxy moiety is considered to be more resistant to degradation than most other types of chemical bonds in vivo, which may be why these lipids have been found to be less well tolerated than cationic lipids with ester linkages for example (Martin, B. et al., Curr. Pharm. Des 11 :375-394 (2005)).
• a variety of these rationally designed lipids were made, characterized, and tested, including those shown in Table 4.
• nucleic acid lipid particles comprising Factor VII siRNA and containing DLinDAP showed significantly reduced in vivo activity as compared to those containing DLinDMA (ED 50 12 - 25 mg/kg), despite its very similar structure to DLinDMA.
• nucleic acid- lipid particles based on DLin-2-DMAP a lipid with one ethoxy linkage and one ester linkage, yielded activity intermediate between DUnDAP- and DUnDMA- based nucleic acid-lipid particles.
• Nucleic acid-lipids particles based on lipids containing carbamate (DLin-C-DAP) or thioether (DLin-S-DMA) linkages also resulted in dramatically reduced in vivo activity.
• the final modification was to insert a ketal ring linker, which introduced interesting structural changes to the lipid molecule.
• the ketal is known to be more acid labile than ethoxy linkers (Martin, B. et al., Curr. Pharm. Des 11 :375-394 (2005)), which may decrease its half-life in the endocytic pathway.
• the hydrocarbon chains now bond to the linker group through a single carbon.
• DODMA 3-(N,N-Dilinoleylamino)-1 ,2-propanediol
• DODAP esters
• Carbamate linked C18:1 chains were also an inactive combination at 10 mg/kg, the maximum dose tested.
• DMDAP was synthesized to determine if the shorter C14:1 hydrocarbon chains might enable the ester-linked lipid through enhanced lipid mixing with the target endosomal membrane (Mui, B. et al., Biochim. Biophys. Acta 1467:281-292 (2000)); however, no activity was observed for DMDAP-LN-siRNA in the FVII model up to a maximum dose of 10 mg/kg.
• the permanently charged, ester linked lipids DLJnTAP and DOTAP were of interest, because the latter lipid is one of the most commonly used cationic lipids for transfection.
• DLin-K-DMA contains a chiral carbon at position 4 of the ketal ring structure. Therefore, the two optically pure (+) and (-) enantiomers were synthesized and their activities compared to that of the racemic mixture. All three formulations exhibited indistinguishable dose responses, each with an ED 50 ⁇ 0.3 mg/kg.
• DLJn-K-TMA permanent positive charge
• DLJn-K 2 -DMA The modification abbreviated as DLJn-K 2 -DMA denotes the presence of two dimethyamine moieties. Within error, this lipid had the same activity as DLJn-K-DMA, despite the larger headgroup.
• the distance between the demethylamino group and the dioxolane linker was varied by introducing additional methylene groups.
• the remaining three lipids were closely related in structure, and were synthesized to determine what effect distancing the positive charge from the dioxolane ring had on activity.
• This parameter can affect both the pK a of the amine headgroup as well as the distance and flexibility of the charge presentation relative to the lipid bilayer interface. Inserting a single additional methylene group into the headgroup (DLJn-K-C2-DMA) produced a dramatic increase in potency relative to DLJn-K-DMA.
• the ED 50 for this lipid was - 0.1 mg/kg, making it 4-fold more potent than DLJn-K-DMA and 10-fold more potent than the DLJnDMA benchmark when compared head-to-head in the FVII model ( Figure 2A).
• Additional methylene groups decreased activity with a significant reduction occurring between DLin-K-C3-DMA (ED 50 ⁇ 0.6 mg/kg) and DLin-K-C4-DMA (ED 50 >3 mg/kg) (Figure 2B).
• Screen 2b Modifications to the headgroup, linker and hydrocarbon chains of DLin-K-DMA and in vivo FVII activity
• DLin-M-DMA does not have a ketal ring linker, but the hydrocarbon chains still bond directly with a single carbon. Interestingly, this lipid remained relatively active with an ED 50 -0.7 mg/kg. Table 7. Miscellaneous modifications to headgroup, linker and hydrocarbon chains of DLin-K-DMA
• nucleic acid-lipid formulations comprising different cationic lipids was further explored in mice and rats.
• Each of the tested nucleic acid-lipid formulations was prepared as described above using PEG-C-DOMG as the PEG-lipid.
• the formulations initially tested (which included either DUn-K-DMA, DUn-K-MPZ, DLin-K-C2-DMA, or DLin-K-C4- DMA) reduced residual FVII levels in both mice ( Figure 3) and rats ( Figure 4).
• the DLin-K-C2-DMA formulation showed a remarkably enhanced ability to reduce FVII levels in both mice and rats.
• the activity of the DLin-K- C2-DMA formulation was approximately 2-3-fold greater than the DLin-K-DMA formulation in mice, and approximately 10-20-fold greater than the DLin-K-DMA formulation in rats.
• a comparison of FVII reduction in mice and rats using the DLin-K-DMA formulation or the DLin-K-C2-DMA formulation is shown in Figure 5.
• Formulations having DLin-K-C4-DMA or DLin-K-MPZ (MPZ) as the cationic lipid showed similar activity to each other and to the DLinDMA formulation.
• the liposomal formulation having DLin-K6-DMA as the cationic lipid was also tested in comparison to DLin-K-C2-DMA and DLin-K-DMA.
• the DLin-K6-DMA formulation reduced FVII levels in mice similarly to DLin-K-DMA, as shown in Figure 6.
• Plasma Liver Plasma Liver (mg/kg)
• Rats administered the liposomal formulation containing DLin-K- C2-DMA showed a dose-dependent loss of weight.
• Rats administered 91 mg/kg appeared normal and had normal livers.
• Rats administered 182 mg/kg showed slower movement and a scruffy coat. Their livers were slightly pale, and one of three livers showed some slight mottling.
• rats administered 364 mg/kg one died, and they showed hunched, slower movement, quinting eyes, scruffy coats, piloerection, red/orange uring, with pale and some mottling livers.
• livers obtained from rats treated with 91 mg/kg were normal.
• the livers of rats treated with 182 mg/kg (“10" mg/kg) showed mild to moderate hepatocellular necrosis, centrilobular, and hepatocellular vacuolization.
• One of the livers of the surviving rats treated with 364 mg/kg (“20" mg/kg) showed moderate hepatocellular necrosis, centrilobular, and the other showed diffuse, mild to moderate hepatocellular necrosis (not concentrated in centrilobular region) with mild inflammation.
• mice treated with the liposomal formulation of DI_in-K-C2-DMA also showed a dose-dependent loss of weight, although no mice died. Mice also showed a greater than 10-fold incresase in ALT-AST at approximately 1100 mg/kg lipid. However, the mice showed no obvious clinical signs, except at greater than 1300 mg/kg, where the mouse exhibited hunched, slower movement and a scruffy coat.
• siRNA dose 46 mg/kg (150-fold more than the ED 50 ) was administered before significant toxicity signs were measured.
• This siRNA dose translated to a total lipid dose of 750 mg/kg at the siRNA-to-lipid ratio of 0.06 (wt/wt).
• the increases in serum ALT and AST were relatively modest ( ⁇ 10-fold normal), and it is not until siRNA doses exceeded 61 mg/kg that severe (> 10-fold) increases are observed.
• the maximum dose tested was 92 mg siRNA/kg, equivalent to 1500 mg total lipid/kg. Animals lost 6% body weight but no deaths occurred at any of the doses tested.
• Characteristics of selected nucleic acid- lipid formulations are summarized in Table 10, wherein C2 indicates that the cationic lipid is DLJn-K- C2-DMA; C4 indicates that the cationic lipid is DLin-K-C4-DMA; and MPZ inidctaes that the cationic lipid is DUn-K-MPZ.
• Each of the formulations described below contained PEG-C-DOMG as the PEG-lipid.
• Table 10 Characteristics of Formulations Comprising Various Amino Lipids
• the pK a of the ionizable cationic lipid determines the surface charge on the LNP under different pH conditions.
• the charge state at physiologic pH e.g., in circulation
• plasma protein adsorption, blood clearance and tissue distribution behavior can influence plasma protein adsorption, blood clearance and tissue distribution behavior (Semple, S. C, et al., Adv.
• the fluorescent probe 2-(p-toluidino)-6-napthalene sulfonic acid (TNS), which exhibits increased fluorescence in a hydrophobic environment, can be used to assess surface charge on lipid bilayers. Titrations of surface charge as a function of pH can then be used to determine the apparent pK a (hereafter referred to as pK a ) of constituent lipids (Cullis, P. R., et al., Chem
• DLin-K-C2-DMA has pK a and T BH values that are theoretically favorable for use in siRNA delivery systems.
• the pK a of 6.4 indicates that LNPs based on DLin- KC2-DMA have limited surface charge in circulation, but will become positively charged in endosomes.
• the T BH for DLin-K-C2-DMA is 7 0 C lower than that for DLJnDMA, suggesting that this lipid has improved bilayer destabilizing capacity.
• the data also demonstrate that pK a and T B H do not fully account for the in vivo activity of lipids used in LNPs.
• DLin-K-C3- DMA and DLin-K-C4-DMA have identical pK a and T BH values, yet DLin-KC4- DMA is more than 5-fold less active in vivo.
• DLin-K-C2-DMA and DLin-K-C4-DMA which have very similar pK a and T BH values, exhibit a >30-fold difference in in vivo activity.
• the results presented in Table 11 support the strategy of testing variants of lead lipids, even ones with very similar pK a and T BH values.
• Table 11 11. pKa's of key cationic lipids measured in situ in preformed vesicles using TNS fluorescence titrations
• the potency of LN-siRNA systems containing 40 mole % DLin-K-C2-DMA was such that as little as -100 picomoles of encapsulated siRNA administered as a single i.v. bolus to a mouse was sufficient to knockdown serum concentrations of FVII protein by 50% within 24 h of injection.
• siRNA-to-lipid ratio used in the activity screen was 0.06 wt/wt, which means that positive charge was in excess of negative charge.
• Charge neutralization for formulations containing 40 mole% monobasic cationic lipid occurs at a ratio of approximately 0.17 wt/wt. Consequently, assuming one cationic lipid forms an ion pair with each negative charge on the siRNA backbone, then approximately 35% of the total cationic lipid was associated with siRNA inside the nanoparticle and, therefore, could not contribute to surface charge.
• nucleic acid lipid particles comprising DLin-K-C2-DMA was further validated in the context of nucleic acid- lipid particles formulated for delivery of siRNA in vivo, termed KC2-SNALP. These particles comprise a different ratio of lipids than the PFV-prepared nucleic acid-lipid particles described in Example 16.
• siRNA were encapsulated in SNALP using a controlled step-wise dilution method process described by Jeffs et al.
• KC2-SNALP lipid constituents of KC2-SNALP
• DLin-KC2-DMA cationic lipid
• DPPC dipalmitoylphosphatidylcholine
• SA synthetic cholesterol
• PEG-C-DMA used at a molar ratio of 57.1 :7.1 :34.3:1.4, respectively.
• SNALP were dialyzed against PBS and filter sterilized through a 0.2 ⁇ m filter before use.
• Mean particle sizes were 75-85 nm and 90-95% of the siRNA was encapsulated within the lipid particles.
• the final lipid-to-siRNA ratio in formulations used for in vivo testing was approximately 6.5:1 (wt:wt).
• the KC2-SNALP formulation showed a marked improvement in potency in the mouse FVII model as compared to the DLin-K-C2-DMA formulation described in Example 16.
• the measured ED 50 decreased from -0.1 mg/kg for the DI_in-K-C2-DMA nucleic acid-lipid formulation described in Example 16 to -0.02 mg/kg for the KC2-SNALP formulation (Figure 8A).
• KC2- SNALP was also found to exhibit similar potency in rats (data not shown).
• tolerability is another critical attribute of a suitable nucleic acid-lipid particle delivery system for human use, so the single- dose tolerability of KC2-SNALP was studied in rats. Doses near the efficacious dose level were found to be very well tolerated (data not shown); therefore, single-dose escalation studies were conducted starting at doses -50-fold higher (1 mg/kg) than the observed ED 50 of the formulation. To understand formulation toxicity in the absence of any toxicity or pharmacologic effects resulting from target silencing, these experiments were conducted using the non-targeting control siRNA sequence directed against luciferase described in Example 16. Clinical signs were observed daily, and body weights, serum chemistry, and hematology parameters were measured at 72 hours post-dose.
• KC2-SNALP was very well tolerated at the high dose levels examined (relative to the observed ED 50 dose) with no dose-dependent, clinically significant changes in key serum chemistry or hematology parameters.
• Table 12 Clinical chemistry and hematology parameters in rats
• KC2-SNALP 1 5 8 ⁇ 22 100 ⁇ 14 2 ⁇ 0 44 ⁇ 0 ⁇ 5 6 ⁇ 02 11 6 ⁇ 06 13 ⁇ 2 1000 ⁇ 272
• TTR transthyretin
• Cynomolgus monkeys were treated with a single 15 minute intravenous infusion of KC2-SNALP-formulated siTTR at siRNA doses of 0.03, 0.1 , 0.3 and 1 mg/kg.
• Control animals received a single 15 minute intravenous infusion of PBS or KC2-SNALP-formulated ApoB siRNA at a dose of 1 mg/kg.
• All siRNAs were synthesized by Alnylam and were characterized by electrospray mass spectrometry and anion exchange HPLC. The sequences for the sense and antisense strands of FVII, ApoB, and Control siRNAs have been reported (Akinc, A. et al., Nat. Biotechnol 26:561-569 (2008)).
• siTTR sense 5'- GuAAccAAGAGuAuuccAuTT-3' (SEQ ID NO:37); and siTTR antisense: 5'- AUGGAAuACUCUUGGUuACTT-S' (SEQ ID NO:38), with 2'-0-Me modified nucleotides shown in lower case.
• siRNAs were generated by annealing equimolar amounts of complementary sense and antisense strands.
• Tissues were harvested at 48 hours post-administration, and liver mRNA levels of TTR were determined. A clear dose response was obtained with an apparent ED 50 of -0.3 mg/kg (Figure 8B). A toxicological analysis indicated that the treatment was well tolerated at the dose levels tested, with no treatment-related changes in animal appearance or behavior. No dose- dependent, clinically significant alterations in key clinical chemistry or hematological parameters were observed (Table 13).
• RNAi therapeutics were employed for the discovery of novel lipids for use in next-generation LNP systems to deliver RNAi therapeutics.
• important structure-activity considerations for ionizable cationic lipids were described, and multiple lipids based on the DLJnDMA structure were designed and characterized.
• a SNALP formulation of the best performing lipid (DLin-K-C2-DMA) was well-tolerated in both rodent and non-human primates and exhibited in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents, as well as silencing of a therapeutically significant gene (TTR) in non-human primates.
• TTR therapeutically significant gene
• the TTR silencing achieved in this work represents a significant improvement in activity relative to previous reports of LNP-siRNA mediated silencing in non-human primates.
• the efficacy observed in this study represents the highest level of potency observed for an RNAi therapeutic in non-human primates to date, and highlights the considerable progress that has been made in both RNAi and delivery technologies.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Dispersion Chemistry (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Saccharide Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (1)

Family

ID=42100987

Family Applications (1)

Country Status (9)

Cited By (330)

Families Citing this family (230)